NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
ACEA_AR_agonist_AUC_viability,"Data from the assay component ACEA_AR_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,111.212021812382,4.138982093110389,40.67195454862142,1.60929504354509,8.95647120560566,91.543013352384,percent_activity,2,26.869413616817,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.31215063142359,1.31215063142359,1.03853377097221,20,cell cycle
ACEA_AR_antagonist_80hr,"Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",, , , ,,,Active,2.43532276271958,6.653011234532713,77.65495177380605,1.89016915432694,0.122016065451132,1.71543578628284,log2_fold_induction,2,0.366048196353396,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.36019731276502,1.36019731276502,1.21791711807499,20,nuclear receptor
ACEA_AR_antagonist_AUC_viability,"Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,108.619804099993,3.751877885248763,46.53555860405932,1.66778493146913,9.65026114229828,82.2721143643145,percent_activity,2,28.9507834268948,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.34895282025445,1.34895282025445,0.975739947060025,20,cell cycle
ACEA_ER_80hr,"Data from the assay component ACEA_ER_80hr was analyzed into 2 assay endpoints. 
This assay endpoint, ACEA_ER_80hr_Positive, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, measures of the cells for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_000116.2, , , ,,,Active,52.90136035886897,2.075214730478038,4.129856375135966,0.6159349483705598,8.497331156775092,50.5530166959234,percent_activity,1.30102999566398,25.491993470325276,,0.5109509309953473,0.5109509309953473,-2.5648733773448367,20,nuclear receptor
APR_HepG2_CellCycleArrest_72h_dn,"Data from the assay component APR_HepG2_CellCycleArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,1.16085837878758,1.2519032755728947,37.1378054667725,1.56981623699585,0.0927274815425616,1.1184225773161,log2_fold_induction,2,0.927274815425616,,1.75279746741158,1.41656796324232,1.27820246052264,20,cell cycle
APR_HepG2_CellLoss_24h_dn,"Data from the assay component APR_HepG2_CellLoss_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.839247370915278,1.267703655147972,27.36126979867107,1.43713624852174,0.066202173316075,0.820846391618107,log2_fold_induction,2.30102999566398,0.66202173316075,,1.69824170187649,1.20510209486066,1.00180857251291,20,cell cycle
APR_HepG2_CellLoss_72h_dn,"Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,2.04701558895626,2.3068099917502094,29.786943593640707,1.47402594300979,0.0887379366431112,1.69306256473214,log2_fold_induction,2.30102999566398,0.887379366431112,,1.39845354611515,0.937282033520499,0.853486612706577,20,cell cycle
APR_HepG2_MitoticArrest_72h_up,"Data from the assay component APR_HepG2_MitoticArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",, , , ,,,Active,2.31267396298801,1.6297160339437577,31.117904661834597,1.49301034588707,0.141906560088972,2.25865397549044,log2_fold_induction,2.30102999566398,1.41906560088972,,1.60318949913517,1.1382972409395,0.969560585509849,20,cell cycle
APR_HepG2_P-H2AX_72h_up,"Data from the assay component APR_HepG2_P-H2AX_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",NP_002096.1, , , ,,,Active,1.4184754649948,1.2934977320382541,39.35536605689936,1.59500395626349,0.109661998615151,1.33192199878439,log2_fold_induction,2.30102999566398,1.09661998615151,,1.91139318390101,1.28595380297651,1.02792141685157,20,dna binding
ATG_AP_1_CIS_up,"Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.","NP_005243.1|NP_002219.1", , , ,,,Active,0.6262411418266195,1.0440934528233867,66.06610793686882,1.8199787225593496,0.11995882938125292,0.6261441130687736,log2_fold_induction,2.30102999566398,0.5997941469062646,"[""Borderline active""]",1.9894321072377854,1.8363133468327382,1.700698304536883,20,dna binding
ATG_DR4_LXR_CIS_dn,ATG_DR4_LXR_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_009052.3|NP_005684.2", , , ,,,Active,2.1008080650140295,3.5516577001620986,18.65545695161996,1.2708058912292501,0.11830014277097414,1.9714271972544768,log2_fold_induction,1.84509804001426,0.5915007138548707,,0.8624394418862436,0.5762650886226034,0.3129416935335153,20,nuclear receptor
ATG_DR5_CIS_up,"Data from the assay component ATG_DR5_RAR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_DR5_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA and RARB and RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_000955.1|NP_001277145.1|NP_000957.1", , , ,,,Active,0.6902988386447001,1.1629958526507835,0.579320198280624,-0.2370813293485225,0.11871045577184501,0.677262765977076,log2_fold_induction,1.30102999566398,0.593552278859225,"[""Borderline active""]",0.4927098813546434,-0.21147172367312003,-1.1210329303367161,20,nuclear receptor
ATG_EGR_CIS_up,"Data from the assay component ATG_EGR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_EGR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EGR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_001955.1, , , ,,,Active,0.8724778057795335,1.2505606414548207,50.69584907513587,1.7049724011959815,0.13953386614895374,0.7270648381591494,log2_fold_induction,2.30102999566398,0.6976693307447688,"[""Borderline active""]",2.2927744158587804,1.6706124485438592,0.7718204088686413,20,dna binding
ATG_ERa_TRANS_up,"Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,2.064346292601555,1.8679278577876206,4.70851116459402,0.6728836045350222,0.22103062321117403,2.5767209804701348,log2_fold_induction,1.84509804001426,1.10515311605587,,0.7424762807290052,0.30527945777902316,-0.4066386090373779,20,nuclear receptor
ATG_ERE_CIS_up,"Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,0.9564257282339984,1.8927484319152774,1.0046128158637913,0.0019987141613996215,0.10106210757931403,1.088647357408177,log2_fold_induction,1.84509804001426,0.5053105378965701,,0.16623506065456084,-1.1092105164782615,-3.1788096499102028,20,nuclear receptor
ATG_FXR_TRANS_up,"Data from the assay component ATG_FXR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_FXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001193922.1, , , ,"[27,61,27,61]",[479],Active,1.8429960993840662,2.2248526585813395,96.18643743872668,1.9831138395974222,0.16567354177595192,1.5358300828208515,log2_fold_induction,2.30102999566398,0.8283677088797596,"[""Hit-call potentially confounded by overfitting""]",1.940042159264491,1.7715482553787296,1.516503573247033,20,nuclear receptor
ATG_IR1_CIS_dn,ATG_IR1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_001193922.1, , , ,,,Active,0.7277562838270217,1.4856020321381402,35.24948407301571,1.547152764848493,0.09797459455270192,0.6064635699320797,log2_fold_induction,2.30102999566398,0.4898729727635096,,1.8902933710506287,1.3622081365003105,0.5034199128763688,20,nuclear receptor
ATG_ISRE_CIS_dn,ATG_ISRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_002189.1, , , ,,,Active,1.5964406103459545,2.257973125275128,76.65252947614933,1.8845264908199844,0.14140474857524557,1.3303671752918547,log2_fold_induction,2.30102999566398,0.7070237428762278,,1.8176694365208736,1.588428826336113,1.244444512906352,20,dna binding
ATG_MRE_CIS_up,"Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_MRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_005946.2, , , ,,,Active,1.1884883583194459,1.97609752823975,59.69823565433939,1.7759614960052916,0.12028640705584168,1.0559564059740154,log2_fold_induction,2.30102999566398,0.6014320352792084,,1.7820164723367666,1.5682094358298593,1.226039258354299,20,dna binding
ATG_NRF1_CIS_dn,ATG_NRF1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_005002.3, , , ,,,Active,0.5106358475307744,1.2700331315364184,121.0821871931095,2.08308025732351,0.08041299629924369,0.42552987309648493,log2_fold_induction,2.30102999566398,0.40206498149621844,"[""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",2.2618708010702564,2.0680039740632123,1.7830193110714603,20,dna binding
ATG_NRF2_ARE_CIS_up,"Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF2_ARE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006155.2, , , ,"[61,61]",[478],Active,1.8217732721525295,2.34586700829424,109.14304694744531,2.037996073819411,0.15531769411576343,1.5181443941486,log2_fold_induction,2.30102999566398,0.7765884705788172,"[""Only one conc above baseline, active""]",1.9889738873836043,1.8617243809403479,1.6753737826269373,20,dna binding
ATG_PPARg_TRANS_up,"Data from the assay component ATG_PPARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2, , , ,"[72,36,58,34,163,34,36,58,72,163]",,Active,1.5978870205980273,1.3925363495627738,71.51626543003982,1.8544048275793457,0.2294930428350727,1.4037274041414682,log2_fold_induction,2.30102999566398,1.1474652141753636,"[""Hit-call potentially confounded by overfitting""]",2.0672675325862793,1.7910534314982116,1.3542507315856207,20,nuclear receptor
ATG_PXRE_CIS_up,"Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,"[8,11,60,8,11,60]",,Active,2.1756420557391705,3.2647442749265063,1.9164482766794857,0.28249710250724386,0.13328100901796647,2.2415650232524564,log2_fold_induction,0.845098040014257,0.6664050450898323,,0.05826029390568557,-0.12647882624989787,-0.32022047655585345,20,nuclear receptor
ATG_PXR_TRANS_up,"Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_PXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,"[8,11,60,8,11,60]",,Active,2.108386676702155,1.6368843986701291,2.551958999438314,0.4068736925958585,0.2576097222766731,2.7762270451706685,log2_fold_induction,1.84509804001426,1.2880486113833656,,0.5692627762084035,0.209974790733476,-0.3839757989978042,20,nuclear receptor
ATG_RARa_TRANS_up,"Data from the assay component ATG_RARa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RARa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000955.1, , , ,,,Active,1.3053693205020265,1.1390629888821253,0.7703783594858756,-0.11329592537452919,0.22920055049512475,1.3239891470406493,log2_fold_induction,1.30102999566398,1.1460027524756238,"[""Borderline active"",""Hit-call potentially confounded by overfitting""]",0.5488038765353855,-0.07735308423021939,-0.850705239702749,20,nuclear receptor
ATG_RARg_TRANS_up,"Data from the assay component ATG_RARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000957.1, , , ,,,Active,1.6188004854008355,1.4004389004081248,1.679499069772653,0.22517976763423825,0.23118473571807732,1.694927088444956,log2_fold_induction,1.30102999566398,1.1559236785903866,,0.695821712910609,0.07695614142917376,-0.9047511062431253,20,nuclear receptor
ATG_RORE_CIS_up,"Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.","NP_599023.1|NP_008845.2|NP_005051.2", , , ,,,Active,0.9900683085259163,1.446041225373106,73.4681171690237,1.866098909946714,0.13693500450105905,0.825056923791059,log2_fold_induction,2.30102999566398,0.6846750225052953,"[""Only one conc above baseline, active""]",2.142799710432481,1.748323783693072,1.1130446029076446,20,nuclear receptor
ATG_RXRb_TRANS_up,"Data from the assay component ATG_RXRb_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_RXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_068811.1, , , ,,,Active,1.2899931194875702,1.298569003445055,22.530847320012388,1.3527775245905085,0.19867917932204862,1.4261096567777907,log2_fold_induction,1.84509804001426,0.9933958966102431,,1.4183969349564662,1.3445202669362366,1.2334972105737676,20,nuclear receptor
ATG_TCF_b_cat_CIS_dn,ATG_TCF_b_cat_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_003193.2|NP_001139746.1|NP_057353.1|NP_112573.1", , , ,,,Active,1.2826342297699762,1.8567485370451724,59.36949880154697,1.7735633826191484,0.13815917494257557,1.068861858144805,log2_fold_induction,2.30102999566398,0.6907958747128778,,1.8311256520742891,1.4982989293766429,0.9555273070333383,20,dna binding
ATG_VDRE_CIS_up,"Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000367.1, , , ,,,Active,1.2481826976994463,1.7188446139614215,15.621978203739232,1.1937360275291538,0.1452350826317871,1.1067361628459196,log2_fold_induction,2.30102999566398,0.7261754131589355,,1.3723622159093687,0.8565577522394552,0.004793609994042658,20,nuclear receptor
BSK_3C_HLADR_down,"Data from the assay component BSK_3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2, , , ,,,Active,0.4371693521271467,5.521122411539271,10,1,0.025758990402599997,0.375924155,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy""]",1,1,0.7102005691032007,20,cell adhesion molecules
BSK_3C_Proliferation_down,"Data from the assay component BSK_3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.4024065438399154,3.426098841455698,39.99999999999999,1.6020599913279623,0.0391510930713,0.402151555,log10_fold_induction,1.60205999132796,0.1174532792139,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,0.9301374220380245,20,cell cycle
BSK_3C_SRB_down,"Data from the assay component BSK_3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.4787417522913961,6.046150776706005,10,1,0.02172150128694,0.37184976000000003,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy""]",1,1,0.8054061639715329,20,cell cycle
BSK_3C_VCAM1_down,"Data from the assay component BSK_3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,0.10750868736712908,1.3577544271337467,39.99999999999999,1.6020599913279623,0.0189344513925,0.107509145,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,0.9184690967506122,20,cell adhesion molecules
BSK_3C_Vis_down,"Data from the assay component BSK_3C_Vis was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Vis_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",, , , ,,,Active,0.3010365014312869,3.801866179906082,10,1,0,0.30103,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy""]",1,1,0.8993518041375078,20,cell morphology
BSK_4H_MCP1_down,"Data from the assay component BSK_4H_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,0.22839705865911594,1.414953384734081,39.99999999999999,1.6020599913279623,0.05380555551,0.228389975,log10_fold_induction,1.60205999132796,0.16141666653,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,0.9209246010360949,20,cytokine
BSK_4H_VCAM1_down,"Data from the assay component BSK_4H_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,0.0882398671822187,1.1144036193765559,39.99999999999999,1.6020599913279623,0.0228833401839,0.088234722,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Borderline active"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,0.937841414030553,20,cell adhesion molecules
BSK_CASM3C_Proliferation_down,"Data from the assay component BSK_CASM3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_CASM3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.20306882397227752,2.088192634442629,39.99999999999999,1.6020599913279623,0.032415404055299996,0.15156003499999998,log10_fold_induction,1.60205999132796,0.09724621216589999,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,0.410574437595856,20,cell cycle
BSK_CASM3C_SAA_up,"Data from the assay component BSK_CASM3C_SAA was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_SAA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""apolipoproteins"".",NP_954630.1, , , ,,,Active,0.16078078125422043,1.5845285584544588,10,1,0.033823053213809996,0.13767557000000002,log10_fold_induction,1.60205999132796,0.10146915964143,"[""Less than 50% efficacy""]",1,1,-4.178881307375276,20,cell adhesion molecules
BSK_hDFCGF_IP10_down,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2, , , ,,,Active,0.11742580856745562,1.451745003913834,40.000000000000014,1.6020599913279625,0.0269619913164,0.09692530999999999,log10_fold_induction,1.60205999132796,0.0808859739492,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",1.6020599913279625,1.6020599913279625,1.3941741274721544,20,cytokine
BSK_hDFCGF_Proliferation_down,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.32666450414373094,2.410744431083896,40.000000000000014,1.6020599913279625,0.0451678604517,0.31332425500000005,log10_fold_induction,1.60205999132796,0.1355035813551,"[""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.23220992686687925,20,cell cycle
BSK_LPS_CD40_down,"Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1, , , ,,,Active,0.1712969374835684,1.2410244811121318,40.000000000000014,1.6020599913279625,0.0460095510042,0.1712709,log10_fold_induction,1.60205999132796,0.13802865301259998,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.8731905916768843,20,cytokine
BSK_LPS_TNFa_up,"Data from the assay component BSK_LPS_TNFa was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TNFa_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_000585.2, , , ,,,Active,0.4606738749784174,3.3832856347065854,4,0.6020599913279624,0.04538722854225,0.4278453,log10_fold_induction,1.60205999132796,0.13616168562675,"[""Less than 50% efficacy""]",0.6020599913279624,0.6020599913279624,-0.3753220384224391,20,cytokine
BSK_LPS_VCAM1_down,"Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,0.13760724908719682,1.7378767821414525,40.000000000000014,1.6020599913279625,0.0224178208338,0.13709924,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.7984727489902723,20,cell adhesion molecules
BSK_SAg_CD38_down,"Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""other cytokine"".",NP_001766.2, , , ,,,Active,0.13602967799863824,1.7179532375232014,40.000000000000014,1.6020599913279625,0.0243080164845,0.1106717775,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.41785181742537414,20,cytokine
BSK_SAg_CD40_down,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1, , , ,,,Active,0.22339123359244856,2.2406670995741345,10,1,0.0332328459435,0.20856269500000002,log10_fold_induction,1.60205999132796,0.09969853783049999,"[""Less than 50% efficacy""]",1,1,0.43063821364968435,20,cytokine
BSK_SAg_Proliferation_down,"Data from the assay component BSK_SAg_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.43874557817685245,3.6659967790856913,10,1,0.0398932500141,0.39507064000000003,log10_fold_induction,1.60205999132796,0.1196797500423,"[""Less than 50% efficacy""]",1,1,0.591099314315953,20,cell cycle
BSK_SAg_SRB_down,"Data from the assay component BSK_SAg_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.11676589308076647,1.474666021428051,40.000000000000014,1.6020599913279625,0.017346765986949,0.115532275,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.6020599913279625,1.6020599913279625,0.6716503885616383,20,cell cycle
CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength_loss,"Data from the CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,98.92183041938199,3.297394347312733,9.169960855603874,0.962367481773454,7.094741702808024,96.17916612882406,percent activity,1.47712125471966,30,,0.7518728103232311,0.6348775282735277,0.4063231928574371,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength_loss,"Data from the CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,98.92183041938199,3.297394347312733,9.169960855603874,0.962367481773454,7.094741702808024,96.17916612882406,percent activity,1.47712125471966,30,,0.7518728103232311,0.6348775282735277,0.4063231928574371,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_NOG_NeuronCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,73.60926417024321,2.453642139008107,16.905369500939926,1.2280246675871787,8.116887316371168,76.70989066870074,percent activity,1.47712125471966,30,,1.2077174795477357,1.1897782534761514,1.1087443537187616,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_NOG_NeuronCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,73.60926417024321,2.453642139008107,16.905369500939926,1.2280246675871787,8.116887316371168,76.70989066870074,percent activity,1.47712125471966,30,,1.2077174795477357,1.1897782534761514,1.1087443537187616,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,89.4104992241605,2.408159734304884,19.655189366930745,1.2934772323645487,12.376047700170364,96.1496502598986,percent_activity,2,37.128143100511096,,1.274895741696367,1.274895741696367,1.1741969157627947,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,89.4104992241605,2.408159734304884,19.655189366930745,1.2934772323645487,12.376047700170364,96.1496502598986,percent_activity,2,37.128143100511096,,1.274895741696367,1.274895741696367,1.1741969157627947,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,97.85509846700458,3.2618366155668195,11.455623766399265,1.059018741795147,7.809103377083028,97.79413876380082,percent_activity,1.47712125471966,30,,0.9677146061658372,0.9297074644333827,0.8132195399380145,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,97.85509846700458,3.2618366155668195,11.455623766399265,1.059018741795147,7.809103377083028,97.79413876380082,percent_activity,1.47712125471966,30,,0.9677146061658372,0.9297074644333827,0.8132195399380145,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,94.6819492813474,3.1560649760449135,22.208296732033848,1.3465152515586212,9.266250000000007,98.27721221613156,percent activity,2,30,,1.3048075202896743,1.2988537794098798,1.2272349359605126,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,94.6819492813474,3.1560649760449135,22.208296732033848,1.3465152515586212,9.266250000000007,98.27721221613156,percent activity,2,30,,1.3048075202896743,1.2988537794098798,1.2272349359605126,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,101.76137515018866,2.988801017681841,11.930931513027504,1.0766743527377771,11.349185905224777,99.95342262848628,percent_activity,2,34.04755771567433,,0.9867536792315351,0.9867536792315351,0.7893045616490786,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,101.76137515018866,2.988801017681841,11.930931513027504,1.0766743527377771,11.349185905224777,99.95342262848628,percent_activity,2,34.04755771567433,,0.9867536792315351,0.9867536792315351,0.7893045616490786,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,93.47929778179841,3.1159765927266134,20.975882596099307,1.321720243567552,6.844875346260387,92.6265806451613,percent activity,2,30,,1.2810313853310091,1.2529068951366853,1.2024399274185507,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,93.47929778179841,3.1159765927266134,20.975882596099307,1.321720243567552,6.844875346260387,92.6265806451613,percent activity,2,30,,1.2810313853310091,1.2529068951366853,1.2024399274185507,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,100.57597642246532,3.054220084884606,12.098294054832419,1.0827241360350368,10.976722221189164,98.7651267469247,percent activity,1.47712125471966,32.93016666356749,,0.9966446584998471,0.9966446584998471,0.8199974691228455,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,100.57597642246532,3.054220084884606,12.098294054832419,1.0827241360350368,10.976722221189164,98.7651267469247,percent activity,1.47712125471966,32.93016666356749,,0.9966446584998471,0.9966446584998471,0.8199974691228455,20,neurodevelopment
CCTE_Mundy_HCI_hN2_NOG_BPCount_loss,"Data from the CCTE_Mundy_HCI_hN2_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_BPCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,74.1262097115904,1.9660011675651075,9.863769990726297,0.9940429365679049,12.568017241379316,75.86206896551724,percent activity,1.47712125471966,37.70405172413795,,1.001206947211856,1.001206947211856,0.5389740492449617,20,neurodevelopment
CCTE_Mundy_HCI_hN2_NOG_BPCount_loss,"Data from the CCTE_Mundy_HCI_hN2_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_BPCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,74.1262097115904,1.9660011675651075,9.863769990726297,0.9940429365679049,12.568017241379316,75.86206896551724,percent activity,1.47712125471966,37.70405172413795,,1.001206947211856,1.001206947211856,0.5389740492449617,20,neurodevelopment
CCTE_Mundy_HCI_hN2_NOG_NeuriteCount_loss,"Data from the CCTE_Mundy_HCI_hN2_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuriteCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,40.86609123355703,1.3622030411185677,10.930290190563005,1.0386316922779026,3.530500354358604,44.72049689440994,percent_activity,1.47712125471966,30,"[""Less than 50% efficacy""]",1.093762780892583,0.9816164938601624,0.9193511618825997,20,neurodevelopment
CCTE_Mundy_HCI_hN2_NOG_NeuriteCount_loss,"Data from the CCTE_Mundy_HCI_hN2_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuriteCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,40.86609123355703,1.3622030411185677,10.930290190563005,1.0386316922779026,3.530500354358604,44.72049689440994,percent_activity,1.47712125471966,30,"[""Less than 50% efficacy""]",1.093762780892583,0.9816164938601624,0.9193511618825997,20,neurodevelopment
CCTE_Mundy_HCI_hN2_NOG_NeuriteLength_loss,"Data from the CCTE_Mundy_HCI_hN2_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,78.57073378195386,2.619024459398462,19.57340951426478,1.2916664824928699,6.958050541516249,51.36393878908849,percent_activity,2,30,,0.8522230822136894,0.36440613428221635,-0.7122940418922354,20,neurodevelopment
CCTE_Mundy_HCI_hN2_NOG_NeuriteLength_loss,"Data from the CCTE_Mundy_HCI_hN2_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,78.57073378195386,2.619024459398462,19.57340951426478,1.2916664824928699,6.958050541516249,51.36393878908849,percent_activity,2,30,,0.8522230822136894,0.36440613428221635,-0.7122940418922354,20,neurodevelopment
CCTE_Mundy_HCI_hN2_NOG_NeuronCount_loss,"Data from the CCTE_Mundy_HCI_hN2_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,92.71106653244235,2.8568887331025588,49.45067532809432,1.694172226959733,10.817253218884126,76.61764705882354,percent activity,2,32.45175965665238,,1.513902246711253,1.513902246711253,1.054178498023143,20,neurodevelopment
CCTE_Mundy_HCI_hN2_NOG_NeuronCount_loss,"Data from the CCTE_Mundy_HCI_hN2_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,92.71106653244235,2.8568887331025588,49.45067532809432,1.694172226959733,10.817253218884126,76.61764705882354,percent activity,2,32.45175965665238,,1.513902246711253,1.513902246711253,1.054178498023143,20,neurodevelopment
CCTE_Mundy_HCI_hNP1_Casp3_7_gain,"Data from the CCTE_Mundy_HCI_hNP1_Casp3_7 was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Casp3_7_gain in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain -of-signal activity can be used to understand viability effects.",, , , ,,,Active,110.58611469139484,3.686203823046495,11.954344309753068,1.0775257602539277,4.584589533952789,109.68818437793304,percent activity,1.47712125471966,30,,1.0238833893049688,0.9715759164763736,0.9582454452594147,20,cell cycle
CCTE_Mundy_HCI_hNP1_Casp3_7_gain,"Data from the CCTE_Mundy_HCI_hNP1_Casp3_7 was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Casp3_7_gain in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain -of-signal activity can be used to understand viability effects.",, , , ,,,Active,110.58611469139484,3.686203823046495,11.954344309753068,1.0775257602539277,4.584589533952789,109.68818437793304,percent activity,1.47712125471966,30,,1.0238833893049688,0.9715759164763736,0.9582454452594147,20,cell cycle
CCTE_Mundy_HCI_hNP1_Pro_MeanAvgInten_loss,"Data from the CCTE_Mundy_HCI_hNP1_Pro_MeanAvgInten was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_MeanAvgInten_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.",, , , ,,,Active,88.81620689690975,1.6154527871032396,27.24819184999542,1.4353376884246416,18.32638040264677,91.19117230972365,percent_activity,2,54.97914120794031,"[""Borderline active"",""Noisy data""]",1.4616883617521168,1.4616883617521168,1.3160573015446206,20,cell cycle
CCTE_Mundy_HCI_hNP1_Pro_MeanAvgInten_loss,"Data from the CCTE_Mundy_HCI_hNP1_Pro_MeanAvgInten was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_MeanAvgInten_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.",, , , ,,,Active,88.81620689690975,1.6154527871032396,27.24819184999542,1.4353376884246416,18.32638040264677,91.19117230972365,percent_activity,2,54.97914120794031,"[""Borderline active"",""Noisy data""]",1.4616883617521168,1.4616883617521168,1.3160573015446206,20,cell cycle
CCTE_Mundy_HCI_hNP1_Pro_ObjectCount_loss,"Data from the CCTE_Mundy_HCI_hNP1_Pro_ObjectCount was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_ObjectCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.",, , , ,,,Active,81.55420346345151,1.0072812318432047,16.655590501716176,1.2215600346309639,26.988226950354612,92.49249249249249,percent_activity,1.47712125471966,80.96468085106383,"[""Only one conc above baseline, active"",""Borderline active""]",1.4887844342978744,1.4887844342978744,1.1022797177669292,20,cell cycle
CCTE_Mundy_HCI_hNP1_Pro_ObjectCount_loss,"Data from the CCTE_Mundy_HCI_hNP1_Pro_ObjectCount was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_ObjectCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.",, , , ,,,Active,81.55420346345151,1.0072812318432047,16.655590501716176,1.2215600346309639,26.988226950354612,92.49249249249249,percent_activity,1.47712125471966,80.96468085106383,"[""Only one conc above baseline, active"",""Borderline active""]",1.4887844342978744,1.4887844342978744,1.1022797177669292,20,cell cycle
CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten_loss,"Data from the CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.",, , , ,,,Active,100.66488239226746,2.9177360253340416,21.7808869977231,1.3380755618464204,11.500341534008681,99.9999971679411,percent_activity,2,34.50102460202604,"[""Noisy data""]",1.3027269560742027,1.3027269560742027,1.2187952399498243,20,cell cycle
CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten_loss,"Data from the CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.",, , , ,,,Active,100.66488239226746,2.9177360253340416,21.7808869977231,1.3380755618464204,11.500341534008681,99.9999971679411,percent_activity,2,34.50102460202604,"[""Noisy data""]",1.3027269560742027,1.3027269560742027,1.2187952399498243,20,cell cycle
CCTE_Padilla_ZF_144hpf_TERATOSCORE_up,"Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defect  as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""malformation"" intended target family, where the subfamily is ""total"".",, , , ,,,Active,97.5249635550031,4.8762481777501545,6.739852788418615,0.828650410797089,1.53481347591287,98.0740403477554,percent_activity,0.477121254719662,20,"[""Noisy data"",""Noisy data""]",-1.13272150500478,-3.52113221236313,-2.35215795216179,20.100000381469727,malformation
CCTE_Shafer_MEA_acute_burst_number_up,"Data from the assay component CCTE_Shafer_MEA_acute_burst_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_number_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,185.7683545400954,3.713598940712105,4.709472841668299,0.6729722967748701,16.674602140753628,138.32188712840284,percent_activity,1,50.02380642226088,,-0.17939196883429853,-0.17939196883429853,-1.2030981817352164,20,neuroactivity
CCTE_Shafer_MEA_acute_burst_percentage_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_burst_percentage_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_percentage_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,130.5863099050381,2.2281900429614154,0.09792175743079114,-1.009120800716837,19.53548356696422,129.26317716026793,percent_activity,0,58.606450700892665,,-1.0809390350566896,-1.0809390350566896,-1.7768525305618774,20,neuroactivity
CCTE_Shafer_MEA_acute_cross_correlation_area_up,"Data from the assay component CCTE_Shafer_MEA_acute_cross_correlation_area was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_cross_correlation_area_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,198.726112789005,3.969855360966542,0.34181495139246093,-0.4662089446427016,16.68625971808883,200.79399357928733,percent_activity,1,50.05877915426649,,-0.9616158077776226,-0.9616158077776226,-1.4662152687215495,20,neuroactivity
CCTE_Shafer_MEA_acute_cross_correlation_HWHM_dn,"Data from the assay component CCTE_Shafer_MEA_acute_cross_correlation_HWHM was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_cross_correlation_HWHM_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,47.52318605534239,1.5560473037314941,0.3377337578548457,-0.47142552770527446,10.180321626765236,55.680287382128434,percent_activity,0,30.54096488029571,,-0.4253445075575497,-0.4253445075575497,-0.6439421754524565,20,neuroactivity
CCTE_Shafer_MEA_acute_firing_rate_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_firing_rate_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_firing_rate_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,181.78243015990185,3.469465787246579,1.764704267697041,0.2466719359740564,17.464977925239143,138.01216698329236,percent_activity,1,52.39493377571743,,-0.4079244301151698,-0.4079244301151698,-1.3443593533179743,20,neuroactivity
CCTE_Shafer_MEA_acute_network_burst_percentage_up,"Data from the assay component CCTE_Shafer_MEA_acute_network_burst_percentage was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_network_burst_percentage_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,87.93512648229046,2.09042453997865,0.18404588101984307,-0.73507389769773,14.021892810218121,91.9177952088776,percent_activity,0,42.065678430654366,,-0.7527229256065138,-0.7527229256065138,-1.1830370952324547,20,neuroactivity
CCTE_Shafer_MEA_acute_per_burst_spike_number_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_per_burst_spike_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_per_burst_spike_number_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,67.2364241242606,1.4528334712601938,0.10619665949847702,-0.9738891441226798,15.426504013094597,80.28981697929522,percent_activity,0.477121254719662,46.27951203928379,,-0.7856749152929254,-0.7856749152929254,-1.4958947408980405,20,neuroactivity
CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,87.73095928897764,2.2324601217539164,0.10476935403575706,-0.9797657337600052,13.099294724848574,94.70338413188287,percent_activity,0,39.29788417454572,,-1.0216086422236192,-1.0216086422236192,-1.4196359217427572,20,neuroactivity
CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,73.15064979789247,3.545561978115455,0.12497094059771134,-0.9031909614339171,6.877203129753559,78.25031014566018,percent_activity,0.477121254719662,20.631609389260674,,-1.1434329199398792,-1.1434329199398792,-1.4681449090708418,20,neuroactivity
CCTE_Shafer_MEA_acute_per_network_burst_spike_number_std_dn,"Data from the assay component CCTE_Shafer_MEA_acute_burst_spike_number_std was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_spike_number_std_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,74.32565658327839,1.426281101375591,0.33844450509361973,-0.4705125326138257,17.37050209611422,75.15080849582594,percent_activity,1,52.11150628834265,,-0.4239617298739512,-0.4239617298739512,-0.5904700926778347,20,neuroactivity
CCTE_Shafer_MEA_acute_spike_number_up,"Data from the assay component CCTE_Shafer_MEA_acute_spike_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_spike_number_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,181.80214258364333,3.458467896000579,1.8437330588619714,0.26569804282647425,17.522416288619393,137.8316928691085,percent_activity,1,52.567248865858176,,-0.39235391311211354,-0.39235391311211354,-1.3416685932833565,20,neuroactivity
CCTE_Shafer_MEA_acute_synchrony_index_up,"Data from the assay component CCTE_Shafer_MEA_acute_synchrony_index was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_synchrony_index_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,149.3874575507653,3.03570033157652,0.1474196975050737,-0.8314444842773152,16.403404073065456,138.4095567488797,percent_activity,0.477121254719662,49.210212219196364,,-1.1190538103541967,-1.1190538103541967,-1.7204523709834179,20,neuroactivity
CCTE_Shafer_MEA_dev_AB_dn,"Data from the CCTE_Shafer_MEA_dev_AB was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_AB_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,62.9922595879076,3.22944745950648,12.98597041287335,1.11347440904494,6.50186142549743,61.9488767583456,percent activity,1.47712125471966,19.5055842764923,"[""Only highest conc above baseline, active""]",1.06994881062419,1.06994881062419,0.99419151057114,20,cell cycle
CCTE_Shafer_MEA_dev_AB_dn,"Data from the CCTE_Shafer_MEA_dev_AB was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_AB_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,62.9922595879076,3.22944745950648,12.98597041287335,1.11347440904494,6.50186142549743,61.9488767583456,percent activity,1.47712125471966,19.5055842764923,"[""Only highest conc above baseline, active""]",1.06994881062419,1.06994881062419,0.99419151057114,20,cell cycle
CCTE_Shafer_MEA_dev_active_electrodes_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_active_electrodes_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_active_electrodes_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.021819437361,3.7779724055660435,10.464953172285483,1.01973728933371,8.825,100,percent_activity,1.47712125471966,26.475,,0.964270818502499,0.964270818502499,0.900455943621672,20,neurodevelopment
CCTE_Shafer_MEA_dev_active_electrodes_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_active_electrodes_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_active_electrodes_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.021819437361,3.7779724055660435,10.464953172285483,1.01973728933371,8.825,100,percent_activity,1.47712125471966,26.475,,0.964270818502499,0.964270818502499,0.900455943621672,20,neurodevelopment
CCTE_Shafer_MEA_dev_burst_duration_mean_dn,"Data from the CCTE_Shafer_MEA_dev_burst_duration_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_burst_duration_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999879068,1.659195726797679,11.839815453246693,1.07334493310808,24.1080659223316,100,percent activity,1.47712125471966,72.3241977669948,"[""Only highest conc above baseline, active""]",1.20439981883314,1.20439981883314,0.382361056143376,20,neurodevelopment
CCTE_Shafer_MEA_dev_burst_duration_mean_dn,"Data from the CCTE_Shafer_MEA_dev_burst_duration_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_burst_duration_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999879068,1.659195726797679,11.839815453246693,1.07334493310808,24.1080659223316,100,percent activity,1.47712125471966,72.3241977669948,"[""Only highest conc above baseline, active""]",1.20439981883314,1.20439981883314,0.382361056143376,20,neurodevelopment
CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_bursting_electrodes_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.019023439804,2.608527073838141,10.298498656780975,1.01277391668574,12.7810344827586,100,percent_activity,1.47712125471966,38.3431034482758,,0.986970332404221,0.986970332404221,0.893493430149357,20,neurodevelopment
CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_bursting_electrodes_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.019023439804,2.608527073838141,10.298498656780975,1.01277391668574,12.7810344827586,100,percent_activity,1.47712125471966,38.3431034482758,,0.986970332404221,0.986970332404221,0.893493430149357,20,neurodevelopment
CCTE_Shafer_MEA_dev_burst_rate_dn,"Data from the assay component CCTE_Shafer_MEA_dev_burst_rate was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_burst_rate_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999997682,1.6382857897235625,7.648616557601078,0.883582889306121,24.4157644839102,100,percent_activity,1.47712125471966,73.2472934517306,"[""Only highest conc above baseline, active""]",1.09496306249745,1.09496306249745,-0.150897346249328,20,neurodevelopment
CCTE_Shafer_MEA_dev_burst_rate_dn,"Data from the assay component CCTE_Shafer_MEA_dev_burst_rate was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_burst_rate_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999997682,1.6382857897235625,7.648616557601078,0.883582889306121,24.4157644839102,100,percent_activity,1.47712125471966,73.2472934517306,"[""Only highest conc above baseline, active""]",1.09496306249745,1.09496306249745,-0.150897346249328,20,neurodevelopment
CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn,"Data from the CCTE_Shafer_MEA_dev_correlation_coefficient_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn  in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.116670425025,1.963163741868356,12.887850949930575,1.11018050475466,16.9992052946372,100,percent activity,1.47712125471966,50.9976158839116,"[""Only highest conc above baseline, active""]",1.11221804068069,1.11221804068069,0.990897171068313,20,neurodevelopment
CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn,"Data from the CCTE_Shafer_MEA_dev_correlation_coefficient_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn  in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.116670425025,1.963163741868356,12.887850949930575,1.11018050475466,16.9992052946372,100,percent activity,1.47712125471966,50.9976158839116,"[""Only highest conc above baseline, active""]",1.11221804068069,1.11221804068069,0.990897171068313,20,neurodevelopment
CCTE_Shafer_MEA_dev_firing_rate_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_firing_rate_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_firing_rate_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,114.911771730957,1.6258376074591165,9.294036045571376,0.968204352494301,23.5595017205814,100,percent_activity,1.47712125471966,70.6785051617442,"[""Only highest conc above baseline, active""]",1.09264736581673,1.09264736581673,0.384782027538146,20,neurodevelopment
CCTE_Shafer_MEA_dev_firing_rate_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_firing_rate_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_firing_rate_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,114.911771730957,1.6258376074591165,9.294036045571376,0.968204352494301,23.5595017205814,100,percent_activity,1.47712125471966,70.6785051617442,"[""Only highest conc above baseline, active""]",1.09264736581673,1.09264736581673,0.384782027538146,20,neurodevelopment
CCTE_Shafer_MEA_dev_interburst_interval_mean_dn,"Data from the CCTE_Shafer_MEA_dev_interburst_interval_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_interburst_interval_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999821478678,1.8562038723838827,24.545872060004417,1.38997846622281,21.5493249895668,100,percent activity,1.47712125471966,64.6479749687004,"[""Only highest conc above baseline, active""]",1.39840631799649,1.39840631799649,1.27069814919682,20,neurodevelopment
CCTE_Shafer_MEA_dev_interburst_interval_mean_dn,"Data from the CCTE_Shafer_MEA_dev_interburst_interval_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_interburst_interval_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999821478678,1.8562038723838827,24.545872060004417,1.38997846622281,21.5493249895668,100,percent activity,1.47712125471966,64.6479749687004,"[""Only highest conc above baseline, active""]",1.39840631799649,1.39840631799649,1.27069814919682,20,neurodevelopment
CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.99999749354,1.4086385210661383,9.56961477101759,0.980894455416477,28.3962127730534,100,percent_activity,1.47712125471966,85.1886383191602,"[""Noisy data"",""Only highest conc above baseline, active"",""Borderline active""]",1.25752330743498,1.25752330743498,0.301713327729487,20,neurodevelopment
CCTE_Shafer_MEA_dev_LDH_dn,"Data from the assay component CCTE_Shafer_MEA_dev_LDH was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_LDH_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,92.7673169016844,3.8823142525532464,11.632892762736752,1.0656877245889,7.96495001580351,92.1064214799237,percent_activity,1.47712125471966,23.8948500474105,"[""Only highest conc above baseline, active""]",1.0082199670049,1.0082199670049,0.946407221142711,20,cell cycle
CCTE_Shafer_MEA_dev_LDH_dn,"Data from the assay component CCTE_Shafer_MEA_dev_LDH was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_LDH_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,92.7673169016844,3.8823142525532464,11.632892762736752,1.0656877245889,7.96495001580351,92.1064214799237,percent_activity,1.47712125471966,23.8948500474105,"[""Only highest conc above baseline, active""]",1.0082199670049,1.0082199670049,0.946407221142711,20,cell cycle
CCTE_Shafer_MEA_dev_mutual_information_norm_dn,"Data from the CCTE_Shafer_MEA_dev_mutual_information_norm was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_mutual_information_norm_dn  in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.012006129051,1.3820238248066428,9.679038330640276,0.985832209741913,24.1221133658926,100,percent activity,1.47712125471966,72.3663400976778,"[""Only highest conc above baseline, active""]",1.03807091792981,1.03807091792981,0.866551863549451,20,neurodevelopment
CCTE_Shafer_MEA_dev_mutual_information_norm_dn,"Data from the CCTE_Shafer_MEA_dev_mutual_information_norm was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_mutual_information_norm_dn  in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.012006129051,1.3820238248066428,9.679038330640276,0.985832209741913,24.1221133658926,100,percent activity,1.47712125471966,72.3663400976778,"[""Only highest conc above baseline, active""]",1.03807091792981,1.03807091792981,0.866551863549451,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_duration_std_dn,"Data from the CCTE_Shafer_MEA_dev_network_spike_duration_std was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_duration_std_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,113.199815649146,1.478185853832853,3.9832249795919252,0.600234836822564,25.5267440053011,100,percent activity,1.47712125471966,76.5802320159033,,0.921474366324669,0.921474366324669,-0.3564982491195,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_duration_std_dn,"Data from the CCTE_Shafer_MEA_dev_network_spike_duration_std was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_duration_std_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,113.199815649146,1.478185853832853,3.9832249795919252,0.600234836822564,25.5267440053011,100,percent activity,1.47712125471966,76.5802320159033,,0.921474366324669,0.921474366324669,-0.3564982491195,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_network_spike_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999947942,1.5329738472859007,0.6996430562707898,-0.155123471741347,26.0930739643514,100,percent_activity,1.47712125471966,78.2792218930542,,0.575373283827011,0.575373283827011,-2.70574953558103,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_network_spike_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999947942,1.5329738472859007,0.6996430562707898,-0.155123471741347,26.0930739643514,100,percent_activity,1.47712125471966,78.2792218930542,,0.575373283827011,0.575373283827011,-2.70574953558103,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_peak_dn,"Data from the CCTE_Shafer_MEA_dev_network_spike_peak was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_peak_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.032696675872,3.6904922780978304,10.992704799191385,1.04110456547484,9.03517192629845,100,percent activity,1.47712125471966,27.1055157788953,,0.987375568867665,0.987375568867665,0.921824189931137,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_peak_dn,"Data from the CCTE_Shafer_MEA_dev_network_spike_peak was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_peak_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.032696675872,3.6904922780978304,10.992704799191385,1.04110456547484,9.03517192629845,100,percent activity,1.47712125471966,27.1055157788953,,0.987375568867665,0.987375568867665,0.921824189931137,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn,"Data from the CCTE_Shafer_MEA_dev_per_burst_interspike_interval was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999889396,1.7306208703634915,5.841294909038264,0.76650913298765,23.1130923289574,100,percent activity,1.47712125471966,69.3392769868722,"[""Only highest conc above baseline, active""]",1.00742698688287,1.00742698688287,-0.92006965847815,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn,"Data from the CCTE_Shafer_MEA_dev_per_burst_interspike_interval was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999889396,1.7306208703634915,5.841294909038264,0.76650913298765,23.1130923289574,100,percent activity,1.47712125471966,69.3392769868722,"[""Only highest conc above baseline, active""]",1.00742698688287,1.00742698688287,-0.92006965847815,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_burst_spike_percent was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999777151428,3.5380323842971984,24.516241523670107,1.38945389118719,11.305698018671,100,percent_activity,1.47712125471966,33.917094056013,"[""Only highest conc above baseline, active""]",1.33870854423186,1.33870854423186,1.26974138859692,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_burst_spike_percent was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999777151428,3.5380323842971984,24.516241523670107,1.38945389118719,11.305698018671,100,percent_activity,1.47712125471966,33.917094056013,"[""Only highest conc above baseline, active""]",1.33870854423186,1.33870854423186,1.26974138859692,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_spike_percent_up,"Data from the assay component CCTE_Shafer_MEA_dev_per_burst_spike_percent was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_burst_spike_percent_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,50.6776986000189,1.4941639315068176,0.8325789392427492,-0.0795745791402608,11.305698018671,34.1339817244092,percent_activity,1.47712125471966,33.917094056013,"[""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Noisy data"",""Only highest conc above baseline, active""]",0.185678262002895,0.185678262002895,-0.90640108941966,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_spike_percent_up,"Data from the assay component CCTE_Shafer_MEA_dev_per_burst_spike_percent was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_burst_spike_percent_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,50.6776986000189,1.4941639315068176,0.8325789392427492,-0.0795745791402608,11.305698018671,34.1339817244092,percent_activity,1.47712125471966,33.917094056013,"[""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Noisy data"",""Only highest conc above baseline, active""]",0.185678262002895,0.185678262002895,-0.90640108941966,20,neurodevelopment
CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.99999749354,1.4086385210661383,9.56961477101759,0.980894455416477,28.3962127730534,100,percent_activity,1.47712125471966,85.1886383191602,"[""Noisy data"",""Only highest conc above baseline, active"",""Borderline active""]",1.25752330743498,1.25752330743498,0.301713327729487,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.991780439904,2.200140865222814,24.5360249441346,1.38980420449279,18.1794087728033,100,percent_activity,0.477121254719662,54.5382263184099,"[""Only one conc above baseline, active"",""Noisy data""]",1.37990017441255,1.37990017441255,1.27052386557815,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.991780439904,2.200140865222814,24.5360249441346,1.38980420449279,18.1794087728033,100,percent_activity,0.477121254719662,54.5382263184099,"[""Only one conc above baseline, active"",""Noisy data""]",1.37990017441255,1.37990017441255,1.27052386557815,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_up,"Data from the CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,215.949447561725,3.9595979212992707,2.106130908231754,0.323485361605302,18.1794087728033,128.515356873867,percent activity,0.477121254719662,54.5382263184099,,-0.137953434495584,-0.137953434495584,-0.610924542499831,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_up,"Data from the CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,215.949447561725,3.9595979212992707,2.106130908231754,0.323485361605302,18.1794087728033,128.515356873867,percent activity,0.477121254719662,54.5382263184099,,-0.137953434495584,-0.137953434495584,-0.610924542499831,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_network_spike_spike_percent was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.019813158603,1.7971768571715077,10.34129970947966,1.01457512494581,18.5512836905804,100,percent_activity,1.47712125471966,55.6538510717412,"[""Only highest conc above baseline, active""]",1.02688087435571,1.02688087435571,0.895293990386226,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_network_spike_spike_percent was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.019813158603,1.7971768571715077,10.34129970947966,1.01457512494581,18.5512836905804,100,percent_activity,1.47712125471966,55.6538510717412,"[""Only highest conc above baseline, active""]",1.02688087435571,1.02688087435571,0.895293990386226,20,neurodevelopment
CCTE_Shafer_MEA_dev_spike_duration_mean_dn,"Data from the CCTE_Shafer_MEA_dev_spike_duration_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_spike_duration_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.091234026408,2.3536813097653333,12.691386265574199,1.10350906217411,14.1751326048452,100,percent activity,1.47712125471966,42.5253978145356,"[""Only highest conc above baseline, active""]",1.08706896760144,1.08706896760144,0.984224826868881,20,neurodevelopment
CCTE_Shafer_MEA_dev_spike_duration_mean_dn,"Data from the CCTE_Shafer_MEA_dev_spike_duration_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_spike_duration_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.091234026408,2.3536813097653333,12.691386265574199,1.10350906217411,14.1751326048452,100,percent activity,1.47712125471966,42.5253978145356,"[""Only highest conc above baseline, active""]",1.08706896760144,1.08706896760144,0.984224826868881,20,neurodevelopment
CCTE_Shafer_MEA_dev_spike_duration_mean_up,"Data from the CCTE_Shafer_MEA_dev_spike_duration_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_spike_duration_mean_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,106.885193059886,2.5134436960717057,1.0073076450072913,0.00316213006113835,14.1751326048452,71.5442404312129,percent activity,1.47712125471966,42.5253978145356,,-0.166289952538833,-0.166289952538833,-0.895330580049194,20,neurodevelopment
CCTE_Shafer_MEA_dev_spike_duration_mean_up,"Data from the CCTE_Shafer_MEA_dev_spike_duration_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_spike_duration_mean_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,106.885193059886,2.5134436960717057,1.0073076450072913,0.00316213006113835,14.1751326048452,71.5442404312129,percent activity,1.47712125471966,42.5253978145356,,-0.166289952538833,-0.166289952538833,-0.895330580049194,20,neurodevelopment
CPHEA_Stoker_NIS_Inhibition_RAIU,"Data from the assay component CPHEA_Stoker_NIS_Inhibition_RAIU was analyzed at the endpoint, CPHEA_Stoker_NIS_Inhibition_RAIU, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Measures of radioactive substrate uptake for loss-of-signal activity can be used to understand the effects on transporter function at the pathway level as they relate to the sodium-iodide symporter, gene SLC5A5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is sodium-iodide symporter (NIS).",, , , ,,,Active,72.12931648249372,1.198693285675981,69.29994111197608,1.8407328655677273,20.057762716678525,68.18196400500464,percent_activity,2,60.173288150035575,"[""Borderline active"",""Only highest conc above baseline, active""]",1.936718101002067,1.936718101002067,1.7102241760906254,20,transporter
CPHEA_Stoker_NIS_Inhibition_RAIU,"Data from the assay component CPHEA_Stoker_NIS_Inhibition_RAIU was analyzed at the endpoint, CPHEA_Stoker_NIS_Inhibition_RAIU, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Measures of radioactive substrate uptake for loss-of-signal activity can be used to understand the effects on transporter function at the pathway level as they relate to the sodium-iodide symporter, gene SLC5A5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is sodium-iodide symporter (NIS).",, , , ,,,Active,72.12931648249372,1.198693285675981,69.29994111197608,1.8407328655677273,20.057762716678525,68.18196400500464,percent_activity,2,60.173288150035575,"[""Borderline active"",""Only highest conc above baseline, active""]",1.936718101002067,1.936718101002067,1.7102241760906254,20,transporter
LTEA_HepaRG_ABCB11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003733.2, , , ,"[27,27]",,Active,0.896245372385657,1.5968659184331289,0.03055423217397999,-1.51492862560128,0.187084246719363,0.82993689617755,log2_fold_induction,-1,0.561252740158089,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",-1.48630265545841,-1.48630265545841,-1.63680853481668,20.030927835051546,transporter
LTEA_HepaRG_ABCB1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000918.2, , , ,,,Active,1.40787459641422,3.7108398262096256,0.04261022382251085,-1.37048618453632,0.126465046759354,1.14369919866814,log2_fold_induction,-1,0.379395140278062,"[""Hit-call potentially confounded by overfitting"",""Noisy data"",""Hit-call potentially confounded by overfitting"",""Noisy data""]",-1.56709350758595,-1.56709350758595,-1.80366419045658,20.030927835051546,transporter
LTEA_HepaRG_ABCC2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000383.1, , , ,,,Active,0.750660019942332,1.7491190681028626,5.396482823811771,0.732110799105225,0.143054873284778,0.716355551041683,log2_fold_induction,1.47712125471966,0.429164619854334,,0.804645444264528,0.804645444264528,0.180368178382904,20.030927835051546,transporter
LTEA_HepaRG_ABCG2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_004818.2, , , ,,,Active,1.3981148511487,2.320001772874781,18.452764289663154,1.26606143422526,0.200878417062049,1.35547436875016,log2_fold_induction,2,0.602635251186147,,1.20212930637054,1.20212930637054,0.760094195870571,20.030927835051546,transporter
LTEA_HepaRG_ACLY_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001087.2, , , ,,,Active,0.893852009247601,2.5531570597071895,0.031442894250112305,-1.50247748492903,0.116698919330631,0.926179532596193,log2_fold_induction,-1,0.350096757991893,"[""Noisy data"",""Hit-call potentially confounded by overfitting"",""Noisy data"",""Hit-call potentially confounded by overfitting""]",-1.52638058248893,-1.52638058248893,-1.62176366572005,20.030927835051546,lyase
LTEA_HepaRG_ACOX1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_009223.2, , , ,,,Active,1.56721139086083,3.874857067617941,0.031206149169482222,-1.50575981985203,0.134818855982927,1.06777060622355,log2_fold_induction,-1,0.404456567948781,,-1.56353677229924,-1.56353677229924,-1.62597628234459,20.030927835051546,oxidase
LTEA_HepaRG_ADK_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_006712.2, , , ,,,Active,1.21026255574116,2.429987941245037,0.04251116593389959,-1.37149698367755,0.166017635341442,1.01797606238146,log2_fold_induction,-1,0.498052906024326,,-1.42237134011162,-1.42237134011162,-1.68402985710225,20.030927835051546,kinase
LTEA_HepaRG_APOA5_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_443200.2, , , ,,,Active,1.69684955662264,1.9838716128655418,85.3006415698036,1.93095229762916,0.285107420866427,1.32539119885867,log2_fold_induction,2,0.855322262599281,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.93183499521798,1.93183499521798,1.81167179831847,20.030927835051546,apolipoprotein
LTEA_HepaRG_BCL2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000624.2, , , ,,,Active,1.21148771649822,2.5509199001474583,61.10559851286921,1.78608100225335,0.15830729879421,0.887246137300399,log2_fold_induction,2,0.47492189638263,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.69190146133922,1.69190146133922,1.3145430452627,20.030927835051546,cell cycle
LTEA_HepaRG_BID_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001187.1, , , ,,,Active,0.813588324738676,1.1656927383746274,0.03130593323567819,-1.50437334528681,0.232648020630518,1.0775465980668,log2_fold_induction,-0.522878745280338,0.697944061891554,"[""Borderline active"",""Borderline active""]",-1.40678075808095,-1.40678075808095,-1.62366040805289,20.030927835051546,cell cycle
LTEA_HepaRG_CASP3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_116786.1, , , ,,,Active,1.62048423606216,3.522396643422786,0.02513154244055496,-1.59978085590147,0.153350535644343,1.04629210229516,log2_fold_induction,-1,0.460051606933029,"[""AC50 less than lowest concentration tested"",""Gain AC50 < lowest conc & loss AC50 < mean conc"",""AC50 less than lowest concentration tested"",""Gain AC50 < lowest conc & loss AC50 < mean conc""]",-1.66059783265243,-1.66059783265243,-1.74421144837523,20.030927835051546,protease
LTEA_HepaRG_CASP8_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_203520.1, , , ,,,Active,0.995813663043718,2.314047121459339,0.08993002030529683,-1.04609530852719,0.143444739998166,0.53075288198868,log2_fold_induction,-0.522878745280338,0.430334219994498,"[""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",-1.20593054935006,-1.20593054935006,-2.33199340789898,20.030927835051546,protease
LTEA_HepaRG_CAT_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001743.1, , , ,,,Active,1.60058447545415,2.8202109655707397,0.03499712118839817,-1.4559676786044,0.189180229776443,0.886199929757825,log2_fold_induction,-1,0.567540689329329,"[""Hit-call potentially confounded by overfitting"",""Hit-call potentially confounded by overfitting""]",-1.48848895180667,-1.48848895180667,-1.575270213548,20.030927835051546,catalase
LTEA_HepaRG_CYP1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000490.1, , , ,"[57,57]",,Active,2.12336958476926,2.357778263287058,26.990689425464698,1.43121397791891,0.300193564683644,2.12069717958378,log2_fold_induction,2,0.900580694050932,,1.40514311644015,1.40514311644015,1.24392090152033,20.030927835051546,cyp
LTEA_HepaRG_CYP2B6_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000758.1, , , ,,,Active,3.95704907391116,5.249077586890067,1.8645372294546305,0.270571059397669,0.251285361310856,3.6007301177367,log2_fold_induction,1,0.753856083932568,,-0.192729707955915,-0.192729707955915,-0.433081723494519,20.030927835051546,cyp
LTEA_HepaRG_CYP2C19_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000760.1, , , ,,,Active,1.14618518976912,2.043797134764925,5.350566979952051,0.728399805052572,0.186937207917646,1.1278515277986,log2_fold_induction,1.47712125471966,0.560811623752938,"[""Hit-call potentially confounded by overfitting"",""Noisy data"",""Borderline active"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Noisy data""]",0.718658596839188,0.718658596839188,0.229075307338916,20.030927835051546,cyp
LTEA_HepaRG_CYP2C8_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000761.3, , , ,,,Active,1.11837009593815,1.7274821271479137,0.03923281417633596,-1.40635053873717,0.215799646271804,0.936924458249955,log2_fold_induction,-0.522878745280338,0.647398938815412,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",-1.30397939573974,-1.30397939573974,-2.11331639634561,20.030927835051546,cyp
LTEA_HepaRG_CYP2E1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000764.1, , , ,,,Active,4.75891847006076,9.936615993396211,29.58204557500564,1.47102820181845,0.159642493756543,3.83067309871054,log2_fold_induction,2,0.478927481269629,,0.354894842782962,0.354894842782962,0.351293107228616,20.030927835051546,cyp
LTEA_HepaRG_CYP3A4_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_059488.2, , , ,,,Active,3.67680298956894,3.098653353455407,4.114245379805968,0.614290190109733,0.395526977922934,3.41223128608372,log2_fold_induction,1.47712125471966,1.1865809337688,,0.34924072363162,0.34924072363162,-0.171324864054795,20.030927835051546,cyp
LTEA_HepaRG_CYP3A5_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000768.1, , , ,,,Active,0.938951368574293,1.2281421325543687,0.03975738621247959,-1.40058217535145,0.254843296413747,1.00885977493887,log2_fold_induction,-0.522878745280338,0.764529889241241,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",-1.16541460757281,-1.16541460757281,-1.75023753838961,20.030927835051546,cyp
LTEA_HepaRG_CYP3A7_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000756.3, , , ,,,Active,1.81219380010978,2.3350381853660354,3.485630142768438,0.542281302602875,0.258695812266514,1.86318884223154,log2_fold_induction,1.47712125471966,0.776087436799542,,0.458937183398595,0.458937183398595,-0.0914597474262199,20.030927835051546,cyp
LTEA_HepaRG_CYP4A11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000769.2, , , ,,,Active,4.08184493362723,6.385701387427027,53.02164615041971,1.72445320704373,0.213072127136213,3.0040685383906,log2_fold_induction,2,0.639216381408639,,0.925377288469931,0.925377288469931,0.681690444337023,20.030927835051546,cyp
LTEA_HepaRG_CYP4A22_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001010969.2, , , ,,,Active,4.73284674109979,5.859360777326087,42.1849821254128,1.62515786942435,0.269247045935707,3.72707330230142,log2_fold_induction,2,0.807741137807121,,1.11720244893323,1.11720244893323,0.919175668506284,20.030927835051546,cyp
LTEA_HepaRG_CYP7A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000771.2, , , ,,,Active,1.36794447153092,2.5468061322204276,0.013337959896764007,-1.87491059270836,0.179040518530855,1.45428203458455,log2_fold_induction,1.47712125471966,0.537121555592565,"[""AC50 less than lowest concentration tested"",""AC50 less than lowest concentration tested""]",-2.50636354298698,-2.50636354298698,-5.05571895657655,20.030927835051546,cyp
LTEA_HepaRG_DDIT3_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001181982.1, , , ,,,Active,1.77603588449759,3.089758263529111,35.69642460054259,1.55262471880081,0.191604621140491,1.7755688125966,log2_fold_induction,2,0.574813863421473,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.51261270955369,1.51261270955369,1.43334439664699,20.030927835051546,dna binding
LTEA_HepaRG_FABP1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001434.1, , , ,,,Active,0.663022107412727,1.3738712164803646,0.02511388519322082,-1.60008609543309,0.160864691309103,1.19271861437552,log2_fold_induction,2,0.482594073927309,"[""AC50 less than lowest concentration tested"",""AC50 less than lowest concentration tested""]",-1.54642681170813,-1.54642681170813,-1.71992370298486,20.030927835051546,transporter
LTEA_HepaRG_FAS_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000034.1, , , ,,,Active,0.787552637074681,1.4118053104129646,0.03282905033104341,-1.48374168022993,0.185944580145241,0.77403462767722,log2_fold_induction,-1,0.557833740435723,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",-1.43378586880448,-1.43378586880448,-1.60746076151404,20.030927835051546,cytokine receptor
LTEA_HepaRG_FASN_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_004095.4, , , ,"[58,34,34,58]",,Active,1.36360955774919,3.7101419091430614,52.53678574390292,1.72046349866726,0.122511895873739,0.99571887403186,log2_fold_induction,2,0.367535687621217,,0.277156725021146,0.277156725021146,-1.46034486602333,20.030927835051546,lyase
LTEA_HepaRG_FMO3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001002294.1, , , ,,,Active,0.487300898551931,1.1176870475285463,0.02282026629617707,-1.64167929198242,0.145330155887393,0.970379977311824,log2_fold_induction,-0.522878745280338,0.435990467662179,"[""Less than 50% efficacy"",""Noisy data"",""AC50 less than lowest concentration tested"",""Borderline active"",""Less than 50% efficacy"",""Noisy data"",""Borderline active"",""AC50 less than lowest concentration tested""]",-1.5252409214284,-1.5252409214284,-1.76124656909762,20.030927835051546,oxidoreductase
LTEA_HepaRG_FOXO3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001446.1, , , ,,,Active,1.32365547973263,3.450458030577787,0.03327974911446062,-1.47781995637819,0.127872441668368,0.77293878765065,log2_fold_induction,-1,0.383617325005104,"[""Hit-call potentially confounded by overfitting"",""Hit-call potentially confounded by overfitting""]",-1.5522872104151,-1.5522872104151,-1.66037697111366,20.030927835051546,dna binding
LTEA_HepaRG_GCLC_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001489.1, , , ,,,Active,0.822735720459692,1.8757455213673908,0.029102652635996637,-1.53606742432433,0.146205994911991,0.61985029406456,log2_fold_induction,-0.522878745280338,0.438617984735973,"[""Hit-call potentially confounded by overfitting"",""AC50 less than lowest concentration tested"",""Gain AC50 < lowest conc & loss AC50 < mean conc"",""Gain AC50 < lowest conc & loss AC50 < mean conc"",""AC50 less than lowest concentration tested"",""Hit-call potentially confounded by overfitting""]",-1.52883422913048,-1.52883422913048,-1.65585176618453,20.030927835051546,ligase
LTEA_HepaRG_GSTA2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000837.3, , , ,,,Active,2.61687301606118,3.9779394985272436,68.49091026818172,1.835632938174,0.219282119719688,1.94741994532263,log2_fold_induction,2,0.657846359159064,,1.66738471270707,1.66738471270707,1.49686055473057,20.030927835051546,transferase
LTEA_HepaRG_GSTM3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000840.2, , , ,,,Active,1.0004803441251,1.2836739707229834,0.030303497589111977,-1.51850724291722,0.259796066328175,0.875288405212968,log2_fold_induction,-1,0.779388198984525,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active""]",-1.45010808049238,-1.45010808049238,-1.6377903440783,20.030927835051546,transferase
LTEA_HepaRG_HGF_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000592.3, , , ,,,Active,0.716260345372169,1.0088829632638427,0.03144722536909206,-1.50241766691349,0.236651283797079,0.789923785926085,log2_fold_induction,-0.522878745280338,0.709953851391237,"[""Borderline active"",""Borderline active""]",-1.24598739281457,-1.24598739281457,-1.62169798401503,20.030927835051546,growth factor
LTEA_HepaRG_HIF1A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001521.1, , , ,"[122,123,220,150,122,123,220,150]",[801],Active,1.53325352703618,3.880090684362357,0.03151974498921973,-1.50141730483168,0.131719733013418,1.05430634435933,log2_fold_induction,-1,0.395159199040254,,-1.62748472034793,-1.62748472034793,-1.76327466934816,20.030927835051546,dna binding
LTEA_HepaRG_HMGCS2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_005509.1, , , ,"[60,60]",,Active,1.86775761091637,3.5677449901320117,53.23610577971328,1.72620627933011,0.174504027621778,1.51132445083468,log2_fold_induction,2,0.523512082865334,,1.54028562621391,1.54028562621391,1.29301723862567,20.030927835051546,lyase
LTEA_HepaRG_HSPA1A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_005337.2, , , ,,,Active,0.885416003150926,1.8677435889585117,0.03268599713736602,-1.48563826166486,0.158018835916096,0.84566887619292,log2_fold_induction,-1,0.474056507748288,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",-1.47790784261111,-1.47790784261111,-1.60537310580396,20.030927835051546,dna binding
LTEA_HepaRG_ICAM1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000192.2, , , ,,,Active,0.78293143384741,1.3682323615990684,8.845897002018573,0.946741878316945,0.190740368332464,0.864367873159899,log2_fold_induction,2,0.572221104997392,,1.00112277827962,1.00112277827962,0.82714014499231,20.030927835051546,cell adhesion molecules
LTEA_HepaRG_IGF1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,, , , ,,,Active,0.929656091014594,1.9098046936433923,13.796029418115207,1.13975411176896,0.162260237763032,0.73548163072263,log2_fold_induction,2,0.486780713289096,,1.24137868436362,1.24137868436362,-1.2224912321071,20.030927835051546,growth factor
LTEA_HepaRG_IL6R_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000556.1, , , ,,,Active,0.498433617963552,1.272932271114412,0.004988157209195025,-2.30205986754113,0.130521114981027,0.499424517503215,log2_fold_induction,1,0.391563344943081,"[""AC50 less than lowest concentration tested"",""Less than 50% efficacy"",""AC50 less than lowest concentration tested"",""Less than 50% efficacy""]",-0.422242831407315,-0.422242831407315,-5.48286823173755,20.030927835051546,cytokine receptor
LTEA_HepaRG_LIPC_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000227.2, , , ,,,Active,1.14911744377706,2.210456849869004,74.06311004343087,1.8696019449041,0.173285060031091,0.740344738929265,log2_fold_induction,2,0.519855180093273,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.79840366688365,1.79840366688365,1.05054243116605,20.030927835051546,esterase
LTEA_HepaRG_MIR122_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,, , , ,,,Active,1.46420368589237,1.3630541824712425,82.32615162777016,1.9155378145991,0.358069328111801,1.20917277133861,log2_fold_induction,2,1.0742079843354,"[""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active""]",1.97054140826096,1.97054140826096,1.79625744844103,20.030927835051546,microrna
LTEA_HepaRG_MYC_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002458.2, , , ,,,Active,0.909437470204908,1.9354818726980147,24.58214847469616,1.39061983745722,0.15662550379718,0.706415514025895,log2_fold_induction,2,0.46987651139154,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.48350516828744,1.48350516828744,-1.66949695639567,20.030927835051546,dna binding
LTEA_HepaRG_NFE2L2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_006155.2, , , ,"[61,61]",[478],Active,1.28045898450449,4.16664026585075,0.04446652571847539,-1.351966801746,0.102437367823581,0.94140173787337,log2_fold_induction,-1,0.307312103470743,,-1.60761118918495,-1.60761118918495,-1.83927675135857,20.030927835051546,dna binding
LTEA_HepaRG_NFKB1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_068810.3, , , ,,,Active,0.378018406831646,1.071177956278616,0.027017714991131682,-1.56835138398556,0.117633241864225,0.47446121347539,log2_fold_induction,-1,0.352899725592675,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""AC50 less than lowest concentration tested"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""AC50 less than lowest concentration tested"",""Less than 50% efficacy""]",-1.42450929375589,-1.42450929375589,-1.6879520467463,20.030927835051546,dna binding
LTEA_HepaRG_PDK4_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002603.1, , , ,,,Active,0.663593015666778,1.3747905629851669,0.025797737939504316,-1.58841837324066,0.160895541360588,1.10733907918901,log2_fold_induction,-0.522878745280338,0.482686624081764,"[""AC50 less than lowest concentration tested"",""AC50 less than lowest concentration tested""]",-1.53512639094021,-1.53512639094021,-1.70773353125559,20.030927835051546,kinase
LTEA_HepaRG_PPP2R4_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_821068.1, , , ,,,Active,0.34917944502759,1.1003471991335751,28.140774046672053,1.44933603906799,0.105778565560197,0.349160257316455,log2_fold_induction,2,0.317335696680591,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.57415040562054,1.57415040562054,1.33005331378763,20.030927835051546,phosphatase
LTEA_HepaRG_PTEN_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000305.3, , , ,,,Active,1.6219851598746,3.003305667864445,0.052527207321501956,-1.27961568842404,0.180022208775921,1.07226921503615,log2_fold_induction,-1,0.540066626327763,"[""Hit-call potentially confounded by overfitting"",""Hit-call potentially confounded by overfitting""]",-1.4055570130044,-1.4055570130044,-1.67789132359432,20.030927835051546,phosphatase
LTEA_HepaRG_SDHB_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002991.2, , , ,,,Active,1.55082941308724,2.6115858732265815,0.04761011034511544,-1.32230081196764,0.197942232340639,1.03409180357647,log2_fold_induction,-1,0.593826697021917,"[""Hit-call potentially confounded by overfitting"",""Hit-call potentially confounded by overfitting""]",-1.40776648808158,-1.40776648808158,-1.71580442087145,20.030927835051546,oxidoreductase
LTEA_HepaRG_SLC22A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003048.1, , , ,,,Active,1.4762787119417,2.651920489137308,33.66193351330664,1.52713905786806,0.185560957048395,1.47603484591395,log2_fold_induction,2,0.556682871145185,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.49989041469726,1.49989041469726,1.40785874117565,20.030927835051546,transporter
LTEA_HepaRG_SLCO1B1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_006437.3, , , ,,,Active,0.632226619055021,1.1650594195398374,0.027330163452985883,-1.56335777092287,0.180885371867909,1.12114982800224,log2_fold_induction,-1,0.542656115603727,"[""AC50 less than lowest concentration tested"",""Borderline active"",""AC50 less than lowest concentration tested"",""Borderline active""]",-1.46555937240194,-1.46555937240194,-1.68264227756932,20.030927835051546,transporter
LTEA_HepaRG_STAT3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_644805.1, , , ,,,Active,0.691729722798906,1.5165093641649643,0.03034912757372882,-1.51785378878514,0.152044279919936,0.763341724136445,log2_fold_induction,-1,0.456132839759808,,-1.48195410721227,-1.48195410721227,-1.63724869771028,20.030927835051546,dna binding
LTEA_HepaRG_SULT2A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003158.2, , , ,,,Active,1.60327463475987,2.8567581317819357,0.07913364817090683,-1.10163881223316,0.187073897614124,0.9016198831503,log2_fold_induction,-0.522878745280338,0.561221692842372,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",-1.22862245287476,-1.22862245287476,-1.55250684087846,20.030927835051546,transferase
LTEA_HepaRG_THRSP_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003242.1, , , ,,,Active,2.90522923116679,2.9894650131616167,181.36051351218086,2.25854273680081,0.323940818661091,2.13323636589412,log2_fold_induction,2,0.971822455983273,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.36120785080366,1.36120785080366,-0.607781429884026,20.030927835051546,growth factor
LTEA_HepaRG_TIMP1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_003245.1, , , ,,,Active,0.564938290089893,1.5287382212054803,6.385457080770588,0.80519199017446,0.123181824560391,0.410933797935986,log2_fold_induction,1,0.369545473681173,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only one conc above baseline, active"",""Borderline active""]",0.936367068506956,0.936367068506956,0.352911476121174,20.030927835051546,protease inhibitor
LTEA_HepaRG_UGT1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000454.1, , , ,,,Active,1.5952596428349,2.4085338196143904,1.6537618339730062,0.218472964926948,0.220778803248623,1.56493710903675,log2_fold_induction,1.47712125471966,0.662336409745869,,0.120273370189307,0.120273370189307,-0.4114116998239,20.030927835051546,transferase
LTEA_HepaRG_XBP1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_005071.2, , , ,,,Active,1.22217226554753,2.360061480542363,0.027578227926837142,-1.559433643393,0.172618704445313,0.765962594606933,log2_fold_induction,-1,0.517856113335939,"[""AC50 less than lowest concentration tested"",""Gain AC50 < lowest conc & loss AC50 < mean conc"",""Hit-call potentially confounded by overfitting"",""AC50 less than lowest concentration tested"",""Gain AC50 < lowest conc & loss AC50 < mean conc"",""Hit-call potentially confounded by overfitting""]",-1.57641657883097,-1.57641657883097,-1.68077248729743,20.030927835051546,dna binding
NVS_ADME_hCYP2B6,"Data from the assay component NVS_ADME_hCYP2B6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2B6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2B6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000758.1, , , ,,,Active,78.8151034192795,3.9407551709639748,4.789728543497455,0.680310900595812,1.55763530034319,65.6792528505128,percent_activity,1.30102999566398,20,,0.250181308151478,-0.421944444799386,-0.195855543323168,20,cyp
NVS_ADME_hCYP2C19,"Data from the assay component NVS_ADME_hCYP2C19 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C19, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C19. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000760.1, , , ,,,Active,56.2048007684711,2.8102400384235553,3.6350992298567952,0.56051627059837,2.60299124232151,46.8373340372812,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.189032220051762,-0.581329101328782,-0.814866461785519,20,cyp
NVS_ENZ_hDUSP3,"Data from the assay component NVS_ENZ_hDUSP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hDUSP3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DUSP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""dual-specific phosphatase"".",NP_004081.1, , , ,,,Active,39.9825700123343,1.999128500616715,40.90856802257186,1.61181427757269,1.28111925368239,33.3188084297259,percent_activity,1.69897000433602,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.61186160912207,1.49015579388766,1.49253396381666,20,phosphatase
NVS_ENZ_hElastase,"Data from the assay component NVS_ENZ_hElastase was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hElastase, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ELANE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_001963.1, , , ,,,Active,84.2100892177437,4.210504460887185,28.29737040347615,1.4517460796119,1.98040145867003,83.3333333333333,percent_activity,1.69897000433602,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.38842039205752,1.3117728448525,1.33245817860107,20,protease
NVS_GPCR_rSST,"Data from the assay component NVS_GPCR_rSST was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rSST, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Sstr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_036851.1, , , ,,,Active,81.0068649486994,3.2590538354637943,27.722560682834246,1.44283334278906,4.14265760546887,67.5057208237986,percent_activity,1.69897000433602,24.8559456328132,"[""Hit-call potentially confounded by overfitting"",""Hit-call potentially confounded by overfitting""]",0.665501596277746,-0.186366271093364,-0.652977022676272,20,gpcr
OT_AR_ARSRC1_0480,"Data from the assay component OT_AR_ARSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_005408.1, , , ,,,Active,35.5172153001683,1.775860765008415,35.48254667557752,1.55001478273407,2.45637869822485,34.8703170028818,percent_activity,2,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.56379183763277,1.47726060784197,1.43073422067824,20,nuclear receptor
OT_ERa_EREGFP_0120,"Data from the assay component OT_ERa_GFPERaERE_0120 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ERa_EREGFP_0120, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,35.2327735607292,1.76163867803646,26.91081502396611,1.42992685105439,0.488098765432099,20.2979515828678,percent_activity,1.47712125471966,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.47941511467469,0.859558027762748,1.03057461642832,20,nuclear receptor
OT_ER_ERaERb_1440,"Data from the assay component OT_ER_ERaERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".","NP_000116.2|NP_001428.1", , , ,,,Active,28.8014980545571,1.440074902727855,58.66108732932775,1.76835010870847,1.91268599454975,22.8776529338327,percent_activity,2,20,"[""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.9070731136155,1.53323923206618,1.39700293684983,20,nuclear receptor
OT_ER_ERbERb_0480,"Data from the assay component OT_ER_ERbERb_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERbERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_001428.1, , , ,,,Active,23.9383230043975,1.196916150219875,15.351337743185901,1.18614622666464,3.03794948946985,22.9723991507431,percent_activity,2,20,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.43832898277997,1.11064794914923,0.845155519596705,20,nuclear receptor
OT_ER_ERbERb_1440,"Data from the assay component OT_ER_ERbERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERbERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_001428.1, , , ,,,Active,36.2974315049854,1.81487157524927,40.036057188987044,1.60245130094064,1.48426296250401,31.5527118517967,percent_activity,2,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.64589939938221,1.18492915534186,1.1361411571121,20,nuclear receptor
OT_FXR_FXRSRC1_0480,"Data from the assay component OT_FXR_FXRSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_005408.1|NP_001193922.1", , , ,,,Active,133.753022222922,5.336534455734264,109.89669999236082,2.04098465150788,5.01272964064537,66.1485319516408,percent_activity,2,25.0636482032268,,1.34566400151232,1.06174139707549,0.999609750227125,20,nuclear receptor
OT_FXR_FXRSRC1_1440,"Data from the assay component OT_FXR_FXRSRC1_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_005408.1|NP_001193922.1", , , ,,,Active,91.4761860658962,2.197778209964356,16.35284848422058,1.21359341285133,8.32442378863878,78.61747124284,percent_activity,2,41.6221189431939,,1.12979954225009,0.758826461343608,0.193392624359717,20,nuclear receptor
OT_NURR1_NURR1RXRa_0480,"Data from the assay component OT_NURR1_NURR1RXRa_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_NURR1_NURR1RXRa_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_006177.1|NP_002948.1", , , ,,,Active,93.5923465323243,4.633914522692949,90.5773994772125,1.95701984771248,4.03945070950227,64.5147788499589,percent_activity,2,20.1972535475113,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.8869576404182,1.85355022048295,1.83771336295893,20,nuclear receptor
STM_H9_OrnithineISnorm_perc_dn,"Data from the assay component STM_H9_OrnithineISnorm_perc was analyzed at the assay endpoint STM_H9_OrnithineISnorm_perc_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand relative metabolite change.",, , , ,,,Active,0.45423514393871,2.2488193331042354,0.009877712158134447,-2.00534363356577,0.0673294258980023,0.206176183413626,log2_fold_induction,-1.52287874528034,0.201988277694007,"[""Less than 50% efficacy"",""Borderline active"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only one conc above baseline, active""]",-2.04774301634404,-2.04774301634404,-2.42461260230207,100,metabolite
STM_H9_OrnithineISnorm_perc_dn,"Data from the assay component STM_H9_OrnithineISnorm_perc was analyzed at the assay endpoint STM_H9_OrnithineISnorm_perc_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand relative metabolite change.",, , , ,,,Active,0.45423514393871,2.2488193331042354,0.009877712158134447,-2.00534363356577,0.0673294258980023,0.206176183413626,log2_fold_induction,-1.52287874528034,0.201988277694007,"[""Less than 50% efficacy"",""Borderline active"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only one conc above baseline, active""]",-2.04774301634404,-2.04774301634404,-2.42461260230207,100,metabolite
TAMU_PeakParms_SingleDonor1434_Asystole,"Data from the assay component TAMU_PeakParms_SingleDonor1434_Asystole was analyzed into 1 assay endpoint. This assay endpoint, TAMU_PeakParms_SingleDonor1434_Asystole, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand changes in the cardiac function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cardiomyocyte function intended target family, where the subfamily is cessation of beating.",, , , ,,,Active,102.88557596410321,1.0830060627800338,69.74831522043681,1.843533721633026,9.724331715171544,100,percent_activity,2,95,"[""Borderline active"",""Only highest conc above baseline, active""]",1.9787320481905062,1.7931812253203374,1.72417655460892,20,cardiomyocyte function
TAMU_PeakParms_SingleDonor1434_Chronotropy_Positive,"Data from the assay component TAMU_PeakParms_SingleDonor1434_Chronotropy was analyzed into 2 assay endpoints. This assay endpoint, TAMU_PeakParms_SingleDonor1434_Chronotropy_Positive, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand changes in the cardiac function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cardiomyocyte function intended target family, where the subfamily is elevated beat rate.",, , , ,,,Active,47.21827302447117,9.443654604894235,1.271314990733985,0.10425316801196985,8.715639461504102,49.815102857758426,percent_activity,1,5,"[""Noisy data"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",-0.0323065224346378,0.11806758070290853,-0.036390952557902284,20,cardiomyocyte function
Tanguay_ZF_120hpf_ActivityScore,"Data from the assay component Tanguay_ZF_120hpf_ActivityScore was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_ActivityScore, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,59.8668136275866,2.99334068137933,189.6498626374734,2.27795253248142,2.2401450326604,44.7101378264281,percent_activity,1.77815125038364,20,"[""Less than 50% efficacy"",""Noisy data"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Noisy data"",""Borderline active"",""Only highest conc above baseline, active""]",2.00434823053967,1.45774998223978,1.40645402756655,20,malformation
TOX21_AP1_BLA_Agonist_ch1,"Data from the assay component TOX21_AP1_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,82.4653556921073,4.123267784605365,53.68782730313328,1.72987582882163,2.57591984669775,54.0493417787,percent_activity,1.90308998699194,20,,1.42818222863415,1.12876557241204,1.1478226734486,20,channel 1
TOX21_AP1_BLA_Agonist_ch2,"Data from the assay component TOX21_AP1_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,36.3594672620481,1.706373061164073,7.418188812062501,0.870297883049385,3.55134017774949,30.3711602718,percent_activity,1.30102999566398,21.3080410664969,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.950157265876795,0.667953193810076,0.365513477167202,20,channel 2
TOX21_AP1_BLA_Agonist_ratio,"Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_002219.1, , , ,,,Active,63.1030999994348,3.1551549999717396,21.01244273229622,1.32247654281485,2.7369041511147,52.2812728439,percent_activity,1.90308998699194,20,,1.04897933679316,0.64575797744374,0.539869411867258,20,dna binding
TOX21_AP1_BLA_Agonist_viability,"TOX21_AP1_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle target family, where the subfamily is cytotoxicity.",, , , ,,,Active,53.1254574513239,2.354787817980242,35.87961020359734,1.55484771621859,3.76010222277627,51.4747338137,percent_activity,1.90308998699194,22.5606133366576,,1.52509268877955,1.42638716188651,1.33953539476463,20,cell cycle
TOX21_AR_BLA_Antagonist_ch2,"Data from the assay component TOX21_AR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,70.110652079779,1.3278319711793207,38.464010315151064,1.5850545624543,8.80014108229746,67.9717458473,percent_activity,1.90308998699194,52.8008464937848,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.64559815564383,1.55768303576442,1.46577423632644,20,channel 2
TOX21_AR_BLA_Antagonist_ratio,"Data from the assay component TOX21_AR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,"[307,19,23,111,187,117,307,111,19,23,187,117]",,Active,54.7316284972254,2.097604719710672,34.42405726176306,1.53686205549046,4.34874025461246,52.6654010798,percent_activity,1.90308998699194,26.0924415276748,,1.53180630974106,1.47379963892649,1.41758174134422,20,nuclear receptor
TOX21_AR_BLA_Antagonist_viability,"TOX21_AR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,37.9301225939927,1.6449027907688103,39.562000063645726,1.59727823931159,3.8431979898606,36.3423427127,percent_activity,1.90308998699194,23.0591879391636,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.62109145882823,1.55230341016522,1.47799791783546,20,cell cycle
TOX21_ARE_BLA_Agonist_ch2,"Data from the assay component TOX21_ARE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ARE_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,40.6460137975017,1.2021207154988254,21.382196578296274,1.33005231793691,5.63532060098133,35.7341890371,percent_activity,1.95424250943932,33.811923605888,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.67349418533337,1.25712825310049,0.858088119599976,20,channel 2
TOX21_ARE_BLA_agonist_ratio,"Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_ARE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.  ",NP_006155.2, , , ,"[61,61]",[478],Active,67.0395489295033,3.351977446475165,80.95790311124524,1.90825925099018,2.50978290890691,37.5754248971,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.65058593675702,1.28540730477425,1.24627518179505,20,dna binding
TOX21_ARE_BLA_agonist_viability,"TOX21_ARE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,32.7705082664944,1.1071878301105673,60.0058081730876,1.77819328930763,4.93299441089742,31.7428364872,percent_activity,1.95424250943932,29.5979664653845,"[""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active""]",1.89942529429888,1.76764914103426,1.65891278878843,20,cell cycle
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881,"Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,,,Active,129.268178197067,4.023707199888793,77.49679814884239,1.88928375960289,5.35443940025589,73.6181657513,percent_activity,1.95424250943932,32.1266364015353,,1.56496705743918,1.31694767235038,1.2452646248628,20,nuclear receptor
TOX21_Aromatase_Inhibition,"Data from the assay component TOX21_Aromatase_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_Aromatase_Inhibition, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP19A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.",NP_000094.2, , , ,"[122,123,7,153,25,122,123,7,153,25]",[964],Active,104.079786392039,3.8783473973643527,99.75284122939816,1.99892527441068,4.47268624701549,50.5902442283,percent_activity,1.95424250943932,26.8361174820929,,1.54964426494581,1.18701331038469,1.06517948592959,20,cyp
TOX21_Aromatase_Inhibition_viability,"TOX21_Aromatase_Inhibition_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,36.2333581778794,1.3116759159884646,58.75746903858235,1.76906308040871,4.60395205556223,32.0534580203,percent_activity,1.95424250943932,27.6237123333734,"[""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.87019978814389,1.72703151886371,1.57844573052794,20,cell cycle
TOX21_CASP3_CHO_viability,"The assay component endpoint  TOX21_CASP3_CHO_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,56.0879512727498,2.80439756363749,59.202183357148165,1.77233772365664,2.57636017956492,54.2217316482,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.74029619443958,1.67279418324343,1.65305740918078,20,cell cycle
TOX21_DT40,"Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.",, , , ,,,Active,115.225721637895,4.8009480855057145,34.96094627205227,1.54358317897292,4.0001030208237,90.8615022656,percent_activity,1.95424250943932,24.0006181249422,,1.10041583859318,0.829343857574242,0.814328144831028,20,cell cycle
TOX21_DT40_100,"Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",, , , ,,,Active,113.202388828125,5.248287923359831,34.88433898161482,1.54263049800867,3.59489896137582,100.1636433644,percent_activity,1.95424250943932,21.5693937682549,,1.26403660732495,1.10910907036067,1.11945279501345,20,cell cycle
TOX21_DT40_657,"Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",, , , ,,,Active,171.454218846122,6.543550833023187,81.30132442914811,1.91009762047212,4.36700254498032,96.5075894135,percent_activity,1.95424250943932,26.2020152698819,,1.01534561082889,0.608100416186332,0.762175949671083,20,cell cycle
TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2,"Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,77.1907808166907,3.150917987939092,152.19317422544054,2.18239517501865,4.08297841624554,28.5697839729,percent_activity,1.95424250943932,24.4978704974732,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.91456371130122,1.5990811640207,1.4140312502568,20,nuclear receptor
TOX21_ERb_BLA_Agonist_viability,"TOX21_ERb_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,51.5059128997809,2.5063974461551046,59.26857725051578,1.77282450207171,3.42496311979521,46.6750148578,percent_activity,1.95424250943932,20.5497787187713,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.75058204744512,1.69739360372312,1.65354414396345,20,cell cycle
TOX21_ERb_BLA_Antagonist_ratio,"Data from the assay component TOX21_ERb_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_001428.1, , , ,,,Active,34.4469636630697,1.4203446793568597,12.152323778442176,1.08465933206256,4.04208970819059,31.8450605931,percent_activity,1.60205999132796,24.2525382491435,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.32431455290683,0.915942812988158,0.477080760923068,20,nuclear receptor
TOX21_ERR_Antagonist,"Data from the assay component TOX21_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_004442.3, , , ,,,Active,89.7686754491728,4.248208033217655,56.02605331577719,1.74839003022146,3.52182515338437,63.8957192687,percent_activity,1.95424250943932,21.1309509203062,,1.50422575888547,1.33089645965933,1.29301089621424,20,nuclear receptor
TOX21_ERR_viability,"TOX21_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,55.9471726084074,2.79735863042037,94.33872025682969,1.97468998056808,2.25399102610353,26.0601388551,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.87306812797121,1.63077088742663,1.59386256041693,20,cell cycle
TOX21_ESRE_BLA_viability,"TOX21_ESRE_BLA_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,91.7414999900203,2.0599282717238427,69.14219421335383,1.8397431576714,7.42270991093352,51.087108885,percent_activity,1.90308998699194,44.5362594656011,"[""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active""]",1.82626211440319,1.5761996888215,1.33080415923428,20,cell cycle
TOX21_FXR_BLA_agonist_viability,"TOX21_FXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,100.105470533747,1.8714768800713002,77.05975152275234,1.88682760430751,8.9150153371503,55.7518170305,percent_activity,1.90308998699194,53.4900920229018,"[""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active""]",1.89429563804083,1.83205016531359,1.76754701149681,20,cell cycle
TOX21_FXR_BLA_antagonist_ratio,"Data from the assay component TOX21_FXR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_FXR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001193922.1, , , ,"[27,61,27,61]",[479],Active,82.7889934171789,4.139449670858945,78.06517684772544,1.89245734789133,2.78938673282934,45.5862727643,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.43855473304431,1.02543546793858,1.02070511453877,20,nuclear receptor
TOX21_GR_BLA_Agonist_ch1,"Data from the assay component TOX21_GR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,68.9690432414773,3.1572285800090922,89.05606833136112,1.9496635178816,3.6408008634627,22.6246498291,percent_activity,1.90308998699194,21.8448051807762,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active""]",1.9079264941492,1.85898114742026,1.83038319546319,20,channel 1
TOX21_GR_BLA_Antagonist_ch2,"Data from the assay component TOX21_GR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,114.923410434014,2.305309903284605,71.03302728708464,1.85146032383804,8.30860168158384,68.1539466756,percent_activity,1.90308998699194,49.851610089503,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.81083493985691,1.65570142728214,1.51643957167922,20,channel 2
TOX21_GR_BLA_Antagonist_ratio,"Data from the assay component TOX21_GR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand gene activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000167.1, , , ,"[64,66,214,71,14,318,64,214,66,71,14,318]",,Active,87.9682300226095,2.3110958247229747,79.0868474524407,1.89810426410734,6.34390470252021,47.184274776,percent_activity,1.90308998699194,38.0634282151213,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.81655587617156,1.51060532415486,1.23658930231622,20,nuclear receptor
TOX21_H2AX_HTRF_CHO_Agonist_ratio,"Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is histone.",NP_002096.1, , , ,,,Active,32.1875952308777,1.609379761543885,106.69186325929299,2.02813129968375,1.1538473582706,30.879368034,percent_activity,2.30102999566398,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",2.05502135150625,1.91325099877511,1.90884630538193,20,dna binding
TOX21_H2AX_HTRF_CHO_viability,"TOX21_H2AX_HTRF_CHO_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,98.7526277612434,4.9376313880621705,174.64568771301043,2.24215786666668,2.15763115046871,55.2549701586,percent_activity,2.30102999566398,20,,1.89574969050527,1.57056139657638,1.68681858898154,20,cell cycle
TOX21_MMP_ratio_down,"Data from the assay component TOX21_MMP_ratio was analyzed into 2 assay endpoints. This assay endpoint, TOX21_MMP_ratio_down, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of 6 membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.",, , , ,,,Active,102.980824594962,2.6635142607830433,33.692195978554594,1.52752931820249,6.44391923052108,84.8778234749,percent_activity,1.95424250943932,38.6635153831265,,1.39053349356125,1.13320859489422,0.936074344451102,20,cell morphology
TOX21_NFkB_BLA_agonist_ch1,"Data from the assay component TOX21_NFkB_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_NFkB_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,50.0047504556509,2.500237522782545,77.83216011218242,1.89115908379302,3.27484652838546,25.7394779951,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.86912882481782,1.81466097001583,1.77182321410851,20,channel 1
TOX21_p53_BLA_p2_ch1,"Data from the assay component TOX21_p53_BLA_p2_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,73.1020823936896,3.65510411968448,99.84480816957397,1.99932548691401,2.8966141715805,22.0644241016,percent_activity,1.95424250943932,20,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.94631528712823,1.89058091424424,1.8800451615015,20,channel 1
TOX21_p53_BLA_p2_viability,"TOX21_p53_BLA_p2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,87.2892749009266,2.473420393250267,123.72613092207897,2.09246143218191,5.8818195738939,37.3755460286,percent_activity,1.95424250943932,35.2909174433634,"[""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active""]",1.97029069907119,1.65970618997103,1.39987657664308,20,cell cycle
TOX21_PGC_ERR_Antagonist,"Data from the assay component TOX21_PGC_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",NP_004442.3, , , ,,,Active,51.9036086262633,1.5567452432590498,51.06672017252419,1.70813796561517,5.55685104879492,46.929763771,percent_activity,1.95424250943932,33.3411062927695,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.78317031255664,1.61226157594297,1.42663260256122,20,nuclear receptor
TOX21_PGC_ERR_viability,"TOX21_PGC_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,75.6432553965978,3.7821627698298896,107.42031220858006,2.03108641028363,2.5904653717656,26.5571658942,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.90840407612047,1.77124840358406,1.76764514229197,20,cell cycle
TOX21_PPARd_BLA_Agonist_viability,"TOX21_PPARd_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,82.7503148058217,2.4817003848412025,49.44054352848011,1.69408323655734,5.55736672264977,80.7544360379,percent_activity,1.90308998699194,33.3442003358986,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.67273818609856,1.61932473351099,1.57480291589921,20,cell cycle
TOX21_PR_BLA_Antagonist_ch1,"Data from the assay component TOX21_PR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,44.4273139914148,1.5595406907392335,23.967250079246845,1.3796182074204,4.74790582629342,29.3924933621,percent_activity,1.60205999132796,28.4874349577605,"[""Less than 50% efficacy"",""Borderline active"",""Borderline active"",""Less than 50% efficacy""]",1.58738618604368,1.11089676942233,0.593393224495085,20,channel 1
TOX21_PR_BLA_Antagonist_ch2,"Data from the assay component TOX21_PR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,76.8108621015389,1.8488595767051608,15.259637497205434,1.18354421678837,6.92416585421295,72.4975384923,percent_activity,1.95424250943932,41.5449951252777,,1.22232590040623,0.948667812627127,0.663519281751267,20,channel 2
TOX21_PR_BLA_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3, , , ,,,Active,99.4247648823278,4.971238244116391,15.26621510360404,1.18373137737285,2.51198214229767,76.1202361893,percent_activity,1.95424250943932,20,,0.681719219299008,0.273355237518674,0.383897361637035,20,nuclear receptor
TOX21_PR_BLA_Followup_Antagonist_ch1,"Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,38.9822019173279,1.3589318320998611,37.893237629447086,1.57856171333868,9.56197139461893,31.4987481297,percent_activity,1.95424250943932,28.685914183856788,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.8050487502318746,1.8050487502318746,1.0928777248918622,20,channel 1
TOX21_PR_BLA_Followup_Antagonist_ch2,"Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,93.1727099103861,1.1388507164089576,23.76885661615234,1.37600829080521,27.2709754866379,91.360198037,percent_activity,1.95424250943932,81.81292645991371,"[""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active""]",1.7131069650996276,1.7131069650996276,1.000857341563358,20,channel 2
TOX21_PR_BLA_Followup_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3, , , ,,,Active,95.8430036560935,1.9872813961016766,19.832015191171322,1.29736684642613,8.03803325186715,90.3720355711,percent_activity,1.95424250943932,48.2281995112029,,1.3000385597107225,1.0698366609847463,0.8387518015832476,20,nuclear receptor
TOX21_PR_LUC_Followup_Antagonist,"Data from the assay component TOX21_PR_LUC_Followup_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_LUC_Followup_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is steroidal.",NP_000917.3, , , ,,,Active,118.41233085282,2.389092076772081,23.053519472651868,1.36273723648803,8.26062279781809,97.1333995858,percent_activity,1.95424250943932,49.5637367869085,,1.22909753784792,0.822224495618255,0.46927575386088,20,nuclear receptor
TOX21_PXR_Agonist,"Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,,,Active,164.555277690819,8.22776388454095,93.09180232031592,1.96891143862041,1.80636679455099,81.5690455098,percent_activity,1.95424250943932,20,,1.16373460645589,0.593047984830307,1.07446391609946,20,nuclear receptor
TOX21_PXR_viability,"The assay component endpoint  TOX21_PXR_viability was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,79.591720971741,3.97958604858705,94.52654469578196,1.97555378307105,2.43196946437473,29.6953029795,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.91628428974635,1.85104955788652,1.85627346574299,20,cell cycle
TOX21_RAR_LUC_Agonist_viability,"TOX21_RAR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,86.3428753900435,4.3171437695021755,109.87107281161684,2.04088336510822,1.53553439731881,35.9668907622,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.80874832003002,1.48411599072055,1.61552177611327,20,cell cycle
TOX21_RAR_LUC_Antagonist,"Data from the assay component TOX21_RAR_LUC_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RAR_LUC_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RARA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.",NP_000955.1, , , ,,,Active,71.685369687635,2.4092685221508066,56.587973781500956,1.75272414363903,4.95899959044,57.0169589911,percent_activity,1.95424250943932,29.75399754264,,1.7015269291658,1.55277276564006,1.42482745050785,20,nuclear receptor
TOX21_RAR_LUC_Antagonist_viability,"TOX21_RAR_LUC_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,43.7263864875834,2.18631932437917,79.51220883433632,1.90043381824505,1.81181261800875,25.1148016296,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.87040483062651,1.55730882409835,1.5142570426369,20,cell cycle
TOX21_RORg_LUC_CHO_Antagonist,"Data from the assay component TOX21_RORg_LUC_CHO_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RORg_LUC_CHO_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1F3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_005051.2, , , ,,,Active,99.3027783127834,1.9058113511892711,64.15379157203607,1.80722232883491,8.68420845631059,61.0689775642,percent_activity,1.95424250943932,52.1052507378635,"[""Borderline active"",""Borderline active""]",1.83810704826071,1.48447584604174,1.12123595312045,20,nuclear receptor
TOX21_RORg_LUC_CHO_Antagonist_viability,"TOX21_RORg_LUC_CHO_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,69.9687614514999,3.498438072574995,85.43366420486905,1.93162903342405,3.0881472477345,39.4440130203,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.80385053661935,1.66930404404563,1.6250127284735,20,cell cycle
TOX21_RT_HEK293_FLO_08hr_viability,"TOX21_RT_HEK293_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,41.9777991736023,1.782447802060859,43.83153662726883,1.64178669623109,3.92510785122456,44.0722305969,percent_activity,1.90308998699194,23.5506471073474,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.65510477753086,1.59065297242046,1.52250635419517,20,cell cycle
TOX21_RT_HEK293_FLO_16hr_viability,"TOX21_RT_HEK293_FLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,78.7402781370727,3.1399682580237465,44.83849115872877,1.65165098990725,4.17946253309319,78.7747473968,percent_activity,1.90308998699194,25.0767751985591,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.59388838021874,1.52531929079613,1.48482800397749,20,cell cycle
TOX21_RT_HEK293_FLO_24hr_viability,"TOX21_RT_HEK293_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,125.229654920737,4.661907278604444,41.974394922221855,1.62298444432565,4.47705368342379,123.0662849137,percent_activity,1.90308998699194,26.8623221005427,,1.51035797365074,1.43910771369167,1.43233061084771,20,cell cycle
TOX21_RT_HEK293_FLO_32hr_viability,"TOX21_RT_HEK293_FLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,153.536400792115,5.400521955812972,37.63790576188608,1.57562545053206,4.73831980341741,154.0845957379,percent_activity,1.90308998699194,28.4299188205045,,1.48038739578242,1.42891801636801,1.43439839799414,20,cell cycle
TOX21_RT_HEK293_FLO_40hr_viability,"TOX21_RT_HEK293_FLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,171.485796851625,6.009035204803269,38.601239283653776,1.58660124781716,4.75633195144065,171.8947092096,percent_activity,1.90308998699194,28.5379917086439,,1.472312221733,1.41639684266424,1.43074728491769,20,cell cycle
TOX21_RT_HEK293_GLO_08hr_viability,"TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,71.7712775534359,2.9561299472373115,40.29177996815151,1.60521645361997,4.04646609105207,60.1147656768,percent_activity,1.90308998699194,24.2787965463124,,1.47196228325098,1.28909824018672,1.16884789929171,20,cell cycle
TOX21_RT_HEK293_GLO_16hr_viability,"TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,76.5970559278281,3.1774767799881003,39.71637316000504,1.59896958250932,4.0177086637968,64.9133403203,percent_activity,1.90308998699194,24.1062519827808,,1.45274238747173,1.28364841282295,1.18608380941055,20,cell cycle
TOX21_RT_HEK293_GLO_24hr_viability,"TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,70.2441089793898,2.8629972731582303,37.949789613704326,1.57920937259354,4.08919407864135,66.9998917416,percent_activity,1.90308998699194,24.5351644718481,,1.49428295162396,1.36721934868447,1.27929547049179,20,cell cycle
TOX21_RT_HEK293_GLO_32hr_viability,"TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,81.0844264127064,3.2275749953895327,48.197534300033375,1.68302482107536,4.18706647811088,63.6103165611,percent_activity,1.90308998699194,25.1223988686653,,1.53957515318016,1.37915808573178,1.28948529762541,20,cell cycle
TOX21_RT_HEK293_GLO_40hr_viability,"TOX21_RT_HEK293_GLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,102.161040813945,4.101967769703036,63.68659267361719,1.80404801411363,4.15089564121323,63.2762951438,percent_activity,1.90308998699194,24.9053738472794,,1.55226617804728,1.36486141928774,1.3153525055872,20,cell cycle
TOX21_RT_HEPG2_FLO_08hr_viability,"TOX21_RT_HEPG2_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,76.3503276177311,2.713926408702813,54.845834035477495,1.73914364514472,4.68879869481702,72.1561708864,percent_activity,1.90308998699194,28.1327921689021,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.70989459890651,1.65836942928257,1.61986322985315,20,cell cycle
TOX21_RT_HEPG2_FLO_16hr_ctrl_viability,"TOX21_RT_HEPG2_FLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,96.7643436888879,3.499999454939643,57.952857591654954,1.76307485541074,4.60782660753093,89.7035404751,percent_activity,1.90308998699194,27.6469596451856,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.71332608815968,1.66579368266206,1.64377948735447,20,cell cycle
TOX21_RT_HEPG2_FLO_24hr_viability,"TOX21_RT_HEPG2_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,121.879768742224,4.4432952135327275,51.865810080283886,1.71488116543122,4.57167345723585,116.8838575116,percent_activity,1.90308998699194,27.4300407434151,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.64775936734139,1.60276997824689,1.59560082379569,20,cell cycle
TOX21_RT_HEPG2_FLO_32hr_ctrl_viability,"TOX21_RT_HEPG2_FLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,156.812035181254,5.35546275634103,57.39804022590832,1.75889706428641,4.88012714978376,145.1985004568,percent_activity,1.90308998699194,29.2807628987026,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.6790177262971,1.63548940927779,1.63961667603977,20,cell cycle
TOX21_RT_HEPG2_FLO_40hr_ctrl_viability,"TOX21_RT_HEPG2_FLO_40hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,178.136165887483,6.615134890119892,61.60870316411217,1.78964206718332,4.48809608184861,155.2902643272,percent_activity,1.90308998699194,26.9285764910917,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.69597196246323,1.65371244571391,1.67036165096896,20,cell cycle
TOX21_RT_HEPG2_GLO_08hr_ctrl_viability,"TOX21_RT_HEPG2_GLO_08hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,50.8416230101236,2.54208115050618,41.64709656215354,1.61958472984874,1.79765049419046,42.3587434881,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.59607132621656,1.50387289458443,1.50030441590218,20,cell cycle
TOX21_RT_HEPG2_GLO_16hr_ctrl_viability,"TOX21_RT_HEPG2_GLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,30.137235091009,1.50686175455045,42.6852217261023,1.63027754168302,1.42693580835246,39.2218948513,percent_activity,1.90308998699194,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.66716635159626,1.5326471871588,1.51099722723207,20,cell cycle
TOX21_RT_HEPG2_GLO_24hr_ctrl_viability,"TOX21_RT_HEPG2_GLO_24hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,25.9189037002608,1.29594518501304,41.27129564275977,1.61564810303464,1.22724010465665,34.6335303648,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.68174669526244,1.51801947704372,1.49636778568309,20,cell cycle
TOX21_RXR_BLA_Agonist_viability,"TOX21_RXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,64.5784634688495,2.425003587879988,38.24357309828676,1.58255846164736,4.43837580224682,59.0520460358,percent_activity,1.90308998699194,26.6302548134809,,1.53205781349574,1.39034051751812,1.26926284586561,20,cell cycle
TOX21_SBE_BLA_Antagonist_ch2,"Data from the assay component TOX21_SBE_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,60.6676180663068,1.6535304392123111,48.17811666584803,1.68284981895796,6.11495829646443,56.2008667131,percent_activity,1.90308998699194,36.6897497787866,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.72096399238539,1.6079438334839,1.48597144721676,20,channel 2
TOX21_SBE_BLA_Antagonist_ratio,"Data from the assay component TOX21_SBE_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor receptor intended target family, where subfamily is transforming growth factor beta.",NP_005891.1, , , ,,,Active,89.69335944914,4.396210017265971,61.07320246793957,1.78585069349659,3.40040470833105,61.6530574278,percent_activity,1.90308998699194,20.4024282499863,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.61221504721057,1.49427310795074,1.47381261628368,20,growth factor receptor
TOX21_SHH_3T3_GLI3_Antagonist,"Data from the assay component TOX21_SHH_3T3_GLI3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SHH_3T3_GLI3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",, , , ,,,Active,92.1560455849012,2.0848728163465853,67.59093715542346,1.82988846802372,7.36703975915985,50.4282154762,percent_activity,1.95424250943932,44.2022385549591,"[""Borderline active"",""Borderline active""]",1.79666033337734,1.35932152344664,0.933654729361102,20,dna binding
TOX21_TRHR_HEK293_Agonist,"TOX21_TRHR_HEK293_Agonist  used a type of biochemical reporter where gain-of-signal activity can be used to understand changes in the receptor activation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",, , , ,,,Active,33.2303483087924,1.66151741543962,13.894572564607621,1.14284519122224,0.23532099546207,31.6298608733,percent_activity,1.77815125038364,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.31340757498079,-0.438120648746024,0.235907489759591,20,gpcr
TOX21_TRHR_HEK293_Antagonist,"TOX21_TRHR_HEK293_Antagonist  used a type of biochemical reporter where loss-of-signal activity can be used to understand changes in the receptor activation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",, , , ,,,Active,74.8463680102641,3.742318400513205,114.63393687944637,2.05931320766289,2.87526712790688,28.12650839,percent_activity,1.77815125038364,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.5842938636422,1.0995623553818,1.02469747083886,20,gpcr
TOX21_TR_LUC_GH3_Antagonist,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_003241.2|NP_000452.2", , , ,,,Active,160.710697880724,7.162835542892363,64.40713105890396,1.80893395444179,3.73945711206963,116.7646762496,percent_activity,1.95424250943932,22.4367426724178,,1.54147630786598,1.42806019640028,1.48578159700184,20,nuclear receptor
TOX21_TR_LUC_GH3_Antagonist_viability,"TOX21_TR_LUC_GH3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,157.736044967269,3.9359871621462714,75.76908293760751,1.87949203084786,6.67922423139783,98.1035802385,percent_activity,1.95424250943932,40.075345388387,,1.71244887486318,1.58055563529127,1.53871540795354,20,cell cycle
TOX21_TSHR_HTRF_Agonist_ratio,"Data from the assay component TOX21_TSHR_HTRF_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",, , , ,,,Active,83.9920099202424,3.016113458651104,3.7196023568164076,0.570496514217653,4.64129367543786,84.7797290044,percent_activity,1.60205999132796,27.8477620526272,,0.381815291799624,0.135677247333103,-0.0207638887849594,20,gpcr
TOX21_VDR_BLA_Agonist_viability,"TOX21_VDR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,85.3560793478665,3.1392459061485405,38.012441515466435,1.57992576496331,4.53166577259249,83.242350702,percent_activity,1.90308998699194,27.1899946355549,,1.53864317444187,1.48961202943719,1.46064544600525,20,cell cycle
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist, was analyzed in the positive fitting direction relative to DHT as the baseline of activity. 
Using a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",, , , ,,,Active,70.000353762676,1.8432015104025992,21.284627407762923,1.32806605215615,12.6591971211703,54.5851850472169,percent_activity,2,37.9775913635109,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.47098039249642,1.47098039249642,-0.513131084276987,19.99410057067871,nuclear receptor
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist, was analyzed in the positive fitting direction relative to DHT as the baseline of activity. 
Using a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",, , , ,,,Active,92.6646664351127,1.4587894077627068,56.832122685207295,1.75459387728802,21.1738733368031,65.9675599274771,percent_activity,2,63.5216200104093,"[""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active""]",1.98522351514225,1.98522351514225,1.10422358165351,19.99410057067871,nuclear receptor